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Abstract 
The IGF2 mRNA binding protein p62/IGF2B2-2/IMP2-2 induces hepatic steatosis in mice, is 
overexpressed in HCC patients, and is associated with the overexpression of the tumorigenic 
growth factor IGF2. 
The underlying mechanisms involved in p62’s actions during liver disease are poorly 
characterized. Therefore, the aim of this study was to elucidate the mechanisms of p62 on 
lipogenesis and tumorigenesis. 
Since alterations in hepatic lipid and fatty acid composition are linked to liver pathogenesis, 
we analyzed liver lipids and fatty acid composition of p62 transgenic animals, and found that 
almost all lipid classes and fatty acids were elevated. The elevated ratio of C18 to C16 fatty 
acids was attributed to IGF2-mediated SREBF1 and ELOVL6 activation, and was shown to 
be responsible for steatosis development. Elevated levels of inflammatory markers provided 
evidence that p62 transgenic animals are susceptible to hepatic inflammation. 
Therefore, these results demonstrate an important role of p62 and ELOVL6 in the 
development of steatosis and steatohepatitis. 
Interestingly, though, ELOVL6 was downregulated in HCC patients and in a murine HCC 
model. It therefore seems unlikely that ELOVL6 has a pathophysiological role in HCC. 
Still, p62 amplifies HCC development, which might be attributed to DLK1/RAC1 mediated 
activation of the antiapoptotic ERK pathway. 
Taken together, our data underline the role of p62 in liver pathologies and provide evidence 
for p62 as a prognostic marker or therapeutic target. 
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Zusammenfassung 
Das IGF2 mRNA bindende Protein p62/IGF2B2-2/IMP2-2 induziert im Mausmodell eine 
Fettleber, ist in HCC Patienten überexprimiert und erhöht die Expression des 
Wachstumsfaktors IGF2. 
Die Mechanismen, über die p62 die Leber-Pathophysiologie beeinflusst, sind weitgehend 
unbekannt. Ziel dieser Studie war die Aufklärung der Rolle von p62 in der Lipogenese und 
Karzinogenese. 
Veränderte Lipidstoffwechsel können zur Leberpathogenese beitragen. Die Untersuchung der 
hepatischen Fette aus den Lebern von p62 transgenen Tieren ergab, dass fast alle Lipide und 
Fettsäuren akkumuliert vorlagen. Das erhöhte Verhältnis von C18 zu C16 Fettsäuren, das 
durch eine IGF2-vermittelte Aktivierung von SREBF1 und ELOVL6 verursacht wurde, führte 
zur Steatose in diesen Tieren. Erhöhte inflammatorische Marker in den transgenen Lebern 
ließen auf eine verstärkte Entzündungsneigung schließen.  
Somit scheinen p62 und ELOVL6 eine wichtige Rolle in der Steatose- und der 
Steatohepatitis-Entstehung zu spielen. 
Interessanterweise war ELOVL6 aber im humanen und murinen HCC herrunterreguliert. 
Somit ist eine pathophysiologische Rolle von ELOVL6 in der Hepatokarzinogenese 
unwahrscheinlich. 
Die kanzerogenen Effekte von p62 scheinen durch die verstärkte Expression von DLK1 und 
RAC1, die den antiapoptotischen ERK Signalweg aktivieren, vermittelt zu werden. 
Unsere Daten belegen eine wichtige Rolle von p62 in der Leberpathophysiologie. Somit 
könnte p62 als Biomarker oder therapeutisches Target von Interesse sein. 
  Introduction 
 1
1. Introduction  
  Introduction 
 2
1.1 Steatosis, the first step in liver disease 
Steatosis is described as the accumulation of lipids within hepatocytes (Day and Yeaman, 
1994) and is associated with an imbalance between synthesis, transport, oxidation, and 
storage of hepatic lipids (Koteish and Diehl, 2001). Since also normal livers sometimes 
exhibit lipid containing hepatocytes, steatosis has been defined either as more than 5% of 
cells containing fat droplets (Underwood Ground, 1984) or total lipids exceeding 5% of liver 
weight (Hoyumpa et al., 1975).  
Alcoholic fatty liver disease (AFLD) develops in about 90% of individuals who drink more 
than 60 g alcohol per day (Crabb, 1999). 
Non-alcoholic fatty liver disease (NAFLD) is a form of fatty liver, which is not due to chronic 
alcohol abuse and covers a histological spectrum from simple steatosis to non-alcoholic 
steatohepatitis (NASH) with or without fibrosis and cirrhosis (Neuschwander-Tetri and 
Caldwell, 2003). 
In a large cohort (2,766 subjects, 45-74 years) of Finnish subjects the prevalence of NAFLD 
(21%) was three times higher than the prevalence of AFLD (7%) (Kotronen et al., 2010). 
Similar observations could also be found in China, where the prevalence of NAFLD (15%) 
was also threefold compared to AFLD (4.5%) (Fan, 2013).  
Several risk factors for the development of steatosis have been well described in the literature. 
A wide variety of therapeutic drugs (Fromenty and Pessayre, 1995), obesity (Anderson et al., 
2014), the metabolic syndrome (Kotronen and Yki-Jarvinen, 2008) / type 2 diabetes (Targher 
et al., 2007), and chronic hepatitis B/C virus infections (Nascimento et al., 2012) are 
implicated in steatosis development. For example, patients infected with hepatitis C virus 
develop chronic hepatitis in 60-80% of cases, and up to 20% may progress to cirrhosis 
(Lonardo et al., 2004). 
The prevalence of NAFLD increased in the recent years, which has reached up to 14-34% of 
the general population in Europe, Asia, and America (Armstrong et al., 2012)(Fig. 1.1) and is 
mainly attributed to obesity, overweight, and metabolic disorders in industrialized countries 
(Kopec and Burns, 2011). Since NAFLD is increasing globally and is set to become the 
predominant cause of chronic liver disease, NAFLD is regarded as a global epidemic 
(Loomba and Sanyal, 2013; Ray, 2013). 
The progression from simple steatosis to NASH is best described by the ‘two-hit hypothesis’. 
This hypothesis suggests that a simple steatosis stands for the first hit, which mediates further 
hits by inflammation, lipid peroxidation, and the generation of reactive oxygen species 
(ROS). Persistent oxidative stress leads to the release of pro-inflammatory and pro-fibrogenic 
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cytokines and can thereby induce a progressive hepatic fibrosis or even hepatic cirrhosis (Day 
and James, 1998). 
Hepatocyte injury (hepatocyte ballooning and cell death), inflammatory infiltrates, and / or 
collagen deposition (fibrosis) are characteristics that allow differentiation between simple 
steatosis and NASH (Cohen et al., 2011). ROS and products from lipid peroxidation induce 
fibrosis by activating collagen producing hepatic stellate cells (Browning and Horton, 2004). 
Between 10-20% of patients with simple steatosis develop NASH (Schattenberg and 
Schuppan, 2011)(Fig. 1.1).  
Whereas simple steatosis mostly follows a benign course, NASH might progress to cirrhosis 
in 20-25% of cases over a ten year period (Ratziu et al., 2010)(Fig. 1.1). Liver cirrhosis is 
characterized by the hyper-accumulation of connective tissue components in the liver and can 
finally lead to hepatic failure or hepatocellular carcinoma (HCC) (Matsuda et al., 1997). 
Accordingly, cirrhosis is responsible for around 170,000 deaths / year in Europe (Blachier et 
al., 2013), and could be found in 80% - 90% of the autopsies from HCC patients, therefore 
only 10% to 20% of the HCC cases develop in patients without cirrhosis (Fattovich et al., 
2004). Approximately 7% of cirrhosis patients develop HCC (Shimada et al., 2002)(Fig. 1.1). 
Recently, Ganapathy-Kanniappan et al. presented an interesting hypothesis that early stage 
cirrhotic hepatocytes, which are characterized by metabolic alterations (e.g. increased 
glycolysis), could be linked to the origin of hepatic tumorigenesis and that endstage cirrhotic 
hepatocytes further undergo metabolic adaptation leading to HCC (Ganapathy-Kanniappan et 
al., 2014; Nagrath and Soto-Gutierrez, 2014; Nishikawa et al., 2014). 
 
 
Fig. 1.1: Prevalence of liver disease progression. 
 
The incidence for liver cancer has strongly increased in Germany in the last decades (Fig. 1.2) 
and HCC is responsible for approximately 47,000 deaths per year in Europe (Blachier et al., 
2013). Late diagnosis and inadequate treatment options lead to a high lethality of HCC. 
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Fig. 1.2: Incidence of liver cancer in Germany (Krebsregister Saarland, 2011) 
 
1.2 Pathways involved in the development of NAFLD 
As mentioned above, steatosis occurs when lipid homeostasis linking lipid synthesis, 
degradation, and transport is disturbed. Interestingly, not only the amount of lipids, but also 
the lipid composition of the liver is important in NAFLD (Puri et al., 2007; Puri et al., 2009).  
Lipid synthesis is regulated by a complex network of transcription factors, which are either 
transcriptionally or post-translationally regulated and dependent on metabolic factors like 
insulin, glucose, sterol, and fatty acid levels (Foufelle and Ferre, 2002). The most important 
ones are liver X receptors (LXRs), sterol regulatory element binding transcription factors 
(SREBFs), and carbohydrate element-binding transcription factors (MLXIPLs). They lead to 
a transcriptional activation of a large set of lipogenic genes, including acetyl-CoA 
carboxylase (ACC), fatty acid synthase (FASN), ELOVL fatty acid elongase 6 (ELOVL6), 
and stearoyl CoA desaturase (SCD) as the most important ones (Postic and Girard, 2008). 
Lipid degradation is mainly attributed to peroxisomal oxidation induced by activation of the 
peroxisome proliferator activated receptor alpha (PPARA)(Reddy, 2001) or mitochondrial 
oxidation regulated by carnitine palmitoyl transferase 1 (CPT1)(Reddy and Rao, 2006). 
Lipid trafficking involves export and import of lipids within hepatocytes. Processed lipids are 
bound to apolipoprotein B 100 in hepatocytes and are secreted as very low density lipoprotein 
(VLDL). Lipids can be incorporated into hepatocytes either by a transmembranous flip-flop 
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mechanism, e.g. fatty acid translocase, or by mechanisms involving the liver type fatty acid 
binding proteins (FABPs)(Anderson and Borlak, 2008). 
Interference with these pathways is linked to pathophysiological processes. In this context 
hepatitis (B/C) virus has been described to induce steatosis and to strongly alter hepatic lipid 
content by activation of lipogenic pathways (Kim et al., 2007; Miyoshi et al., 2011; Moriya et 
al., 2001). 
Due to their pathophysiological role directed interference with these pathways may also 
exhibit potential targets for treatment options. For example, inhibition of the lipogenic genes 
SREBF1 and MLXIPL in the liver of obese ob/ob mice (Dentin et al., 2006; Yahagi et al., 
2002) and PPARA agonists, like Fenofibrate as inducer of peroxisomal fatty acid oxidation, 
can ameliorate steatosis (Harano et al., 2006; Kostapanos et al., 2013). Therefore, 
investigation of these pathways may provide excellent targets for the treatment of liver 
pathogenesis. 
 
1.3 Diagnosis and therapy of NAFLD: state of the art 
NAFLD and specifically NASH are underdiagnosed since most of the affected patients are 
symptom free and screenings are inadequate and not performed routinely. Non-invasive 
diagnostics are not sensitive enough in diagnosis or staging of the severity of disease. 
Therefore, liver biopsy is the gold standard for diagnosis but also exhibits some severe risks 
like bleeding, bile leak, and even death (Kopec and Burns, 2011). Laboratory serum analytic 
is limited to some key markers described in the following section.  
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are typically mildly 
elevated, ranging from 1-4 times of the normal levels. The ALT/AST ratio is rarely higher 
than 2. The ALT/AST ratio is often the first evidence for liver pathogenesis and therefore the 
gold standard in laboratory serum analysis (Fracanzani et al., 2008; Kopec and Burns, 2011; 
Wong et al., 2009). Pathophysiological markers like bilirubin and albumin tend to be normal 
and alkaline phosphatase and gamma-glutamyltransferse are only sometimes slightly elevated 
(Kopec and Burns, 2011). Other biomarkers like antinuclear antibody (ANA) and anti-smooth 
muscle antibody (ASMA) have been found to be elevated in only 21% of NAFLD patients 
(Cotler et al., 2004; Vuppalanchi et al., 2012).  
In addition to serological screening, ultra sonography (US) is commonly employed as the 
initial visual tool for diagnosis and has been demonstrated to have a sensitivity of 73% for 
detection of steatosis (Bohte et al., 2011). Newer methods for non-invasive imaging are 
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computerized tomography (CT) and magnetic resonance imaging (MRI), which show only a 
slightly improved sensitivity (Bohte et al., 2011).  
According to the American Association for the Study of the Liver guidelines (AASLD, from 
the year 2012), it is mandatory to treat the liver disease as well as the associated co-
morbidities resulting from the metabolic syndrome (Chalasani et al., 2012). The most 
important recommendation is lifestyle intervention, e.g. weight loss, which can also be 
achieved by bariatric surgery. A reduction of at least 3-5% of body weight in obese patients is 
necessary to improve steatosis, and up to 10% is necessary to improve signs of inflammation.  
Medical treatment is rare and only recommended in biopsy-proven NASH patients with some 
limitations. Pioglitazone, a thiazolidindione and peroxisome proliferator receptor gamma 
agonist, and Vitamin E (alpha-tocopherol, 800 IU/day) are recommended to treat NASH. 
Statins, as 3-hydroxy-3methyl-glutaryl-CoA reductase inhibitors, can be used to reduce 
dyslipidemia in NAFLD and NASH (Chalasani et al., 2012). Other tested substances, i.e. 
Metformin and ursodeoxycholic acid, have no significant effect on liver histology and are not 
recommended for the treatment of liver disease (Chalasani et al., 2012). 
 
1.4 Diagnosis and therapy of HCC: state of the art 
Early detection of HCC is important, because the appearance of symptoms reflects an 
advanced stage where cure is no longer an option. The optimal profile for a curable stage is 
when the HCC is smaller than 2 cm (de Lope et al., 2012). Detection of HCC by imaging 
technologies are identical with those used in NAFLD/NASH diagnostics like US, CT, and 
MRI, and exhibit similar problems in sensitivity (Bruix and Sherman, 2011).  
Serum markers for HCC are only of limited usefulness. Even alpha-fetoprotein (AFP) as the 
most widely used serological marker for HCC, has a limited sensitivity, is not specific for 
HCC, and is only detected in patients with advanced tumors (Sherman, 2010).  
HCC is commonly classified by the Barcelona Clinic Liver Cancer (BCLC) system. The 
BCLC system links the size and number of tumors and liver function to the best treatment 
option (de Lope et al., 2012). Curative treatments are advised only in the very early and early 
stage and are realised by ablation, resection, and in some suitable cases by liver 
transplantation. In the intermediate and advanced stage palliative treatments like 
chemoembolization and treatment with the potent multi-kinase inhibitor sorafenib are 
recommended (Forner et al., 2012).  
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To summarize, there is a lack of diagnostic markers and treatment options in NAFLD and 
HCC. Since NASH and cirrhosis are discussed as risk factors for the development of HCC, it 
is mandatory to develop improved methods to detect and cure hepatic diseases at the earliest 
time before progression to a more severe type. 
 
1.5 The insulin-like growth factor 2 (IGF2) mRNA binding protein p62: a 
potential biomarker and therapeutic target? 
p62 is a splice variant of the IGF2 mRNA binding protein (IMP) 2 IMP2/IGF2BP2 lacking 
exon 10 (Christiansen et al., 2009). The IMP family consists of three different members, 
which share two RNA recognition motives and four hnRNP K homology domains as 
characteristic features, which can bind the 5’-untranslated region of the IGF2-leader 3 mRNA 
(Nielsen et al., 1999) and are implicated in RNA processing (Christiansen et al., 2009; 
Nielsen et al., 2001). p62 was first identified in 1999 as an auto-antigen found in an HCC 
patient (Zhang et al., 1999). In following studies p62 was shown to be overexpressed in HCC 
(33-67.5%) (Kessler et al., 2013; Lu et al., 2001; Qian et al., 2005). Furthermore, p62 was 
suggested as a fetal protein that is re-expressed in cirrhotic tissues and showed strongest 
expression in HCC (Lu et al., 2001). A recent study showed that analysis of a combination of 
14 tumor-associated antigens, among which p62 was one of the important ones, allowed a 
sensitivity of HCC detection up to 69.7%. Furthermore, this array identified 43.8% HCC 
cases, where AFP serum levels were unremarkable (Dai et al., 2014). Liu et al. postulated 
p62/IMP2 also as potential biomarker in diagnosis of ovarian cancer, since 29.4% of ovarian 
cancer patients revealed higher autoantibody response compared to normal individuals (Liu et 
al., 2014). 
Nevertheless, p62 expression levels in NAFLD progression from simple steatosis to HCC are 
rarely characterized. Within the last years the group among Prof. Kiemer was able to unravel 
important pathophysiological features of p62. p62 overexpression induced a steatotic 
phenotype and strongly elevated levels of the tumorigenic growth factor Igf2 in a murine 
model (Tybl et al., 2011), exerts antiapoptotic effects, correlates with IGF2 in human HCC 
samples, and is increased in HCC patients with poor outcome (Kessler et al., 2013). 
Furthermore, p62 was suggested as a pathophysiological regulator in all stages of NAFLD, as 
found in a p62 transgenic mouse model fed a methionine-choline deficient diet (Simon et al., 
2014a; Simon et al., 2014b). 
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Therefore, the pathophysiological role and overexpression in cancer and recurrence of p62 
expression in cirrhosis strongly suggest p62 as a marker and promoter of liver disease 
progression. 
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2. Publications I-IV: 
 
The results of this work are described in the following publications I-IV. 
Each publication should be considered as a ‘stand alone version’ with own figures and 
references. 
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2.1 Rapid chromatographic method to decipher distinct 
alterations in lipid classes in NAFLD/NASH. 
I 
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p62 transgenic animals spontaneously develop a fatty liver phenotype (Tybl et al., 2011). 
Since both the amount of lipids but also the lipid composition plays an important role in liver 
disease (Puri et al., 2007; Puri et al., 2009), the following work was performed to establish an 
easy to use method for qualitative and quantitative analyis of lipid classes and to determine 
alterations in the lipid composition of p62 transgenic livers. 
 
 
Rapid chromatographic method to decipher distinct alterations in lipid classes in 
NAFLD/NASH 
Stephan Laggai, Yvette Simon, Theo Ranssweiler, Alexandra K. Kiemer and Sonja M. 
Kessler. 
 
This research was originally published in the World Journal of Hepatology. Laggai, S., 
Simon, Y., Ranssweiler, T., Kiemer, A.K. and Kessler, S.M. Rapid chromatographic method 
to decipher distinct alterations in lipid classes in NAFLD/NASH. World J Hepatol. 2013; 
5(10):558 -567. doi:10.4254/wjh.v5.i10.558. Copyright ©2013, Baishideng Publishing Group 
Co., Limited. All rights reserved. 
 
The full text article can also be found at: 
http://www.wjgnet.com/1948-5182/pdf/v5/i10/558.pdf 
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2.1.1 Author Contribution 
World J Hepatol 5(10):558-567. Published online 2013 October 27. 
doi:10.4254/wjh.v5.i10.558. 
Rapid chromatographic method to decipher distinct alterations in lipid classes in 
NAFLD/NASH 
Laggai S, Simon Y, Ranssweiler T, Kiemer AK and Kessler SM. 
 
Laggai S: 
Performed sample preparation. 
Performed TLC analysis. 
Designed experiments, performed data acquisition and statistical analysis. 
Wrote and revised the manuscript. 
 
Simon Y: 
Performed MCS/MCD animal procedures. 
Performed histochemistry in MCS/MCD animals. 
Participated in manuscript revision. 
 
Ranssweiler T: 
Assisted in sample preparation. 
Assisted in TLC analysis. 
Participated in manuscript revision. 
 
Kiemer AK: 
Initiated and directed the study. 
Wrote and revised the manuscript. 
 
Kessler SM: 
Performed p62 transgenic animal procedures. 
Performed histochemistry in p62 transgenic animals. 
Initiated and directed the study. 
Wrote and revised the manuscript. 
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2.1.2 Title page 
 
Rapid chromatographic method to decipher distinct alterations in lipid 
classes in NAFLD/NASH 
Rapid chromatography for lipids in NAFLD/NASH 
Stephan Laggai, Yvette Simon, Theo Ranssweiler, Alexandra K. Kiemer, Sonja M. Kessler, 
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2.1.3 Abstract and core tip 
Aim: To establish a simple method to quantify lipid classes in liver diseases and to decipher 
the lipid profile in p62/IMP2-2/IGF2BP2 transgenic mice. 
 
Methods: Liver-specific overexpression of the insulin-like growth factor 2 mRNA binding 
protein p62/IMP2-2/IGF2BP2 was used as a model for steatosis. Steatohepatitis was induced 
by feeding a methionine-choline deficient diet. Steatosis was assessed histologically. For thin 
layer chromatographic analysis, lipids were extracted from the freeze dried tissues by hexane / 
2-propanol, dried, redissolved and chromatographically separated by a two solvent system. 
Dilution series of lipid standards were chromatographed, detected, and quantified. The 
detection was performed by either dichlorofluorescein or sulfuric acid / ethanol. 
 
Results: Histological analyses confirmed steatosis and steatohepatitis development. The 
extraction, chromatographic and detection method showed high inter-assay reproducibility 
and allowed quantification of the different lipid classes. The analyses confirmed an increase 
of triglycerides and phosphatidyletanolamine and a decrease in phosphatidylcholine in the 
methionine-choline deficient diet.  
The method was used for the first time to asses the lipid classes induced in the p62-
overexpressing mouse model and showed a significant increase in all detected lipid species 
with a prominent increase of triglycerides by 2-fold. Interestingly the ratio of 
phosphatidylcholine to phosphatidyletanolamine was decreased, as previously suggested as a 
marker in the progression from steatosis to steatohepatitis. 
 
Conclusion: The TLC analysis allows a reliable quantification of lipid classes and provides 
detailed insight into the lipogenic effect of p62. 
 
Key words: NASH, NAFLD, TLC, IMP2, p62, MCD, polar lipids, neutral lipids, PC/PE 
ratio, triglycerides 
 
List of abbreviations: NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic 
steatohepatitis; HCC, hepatocellular carcinoma; VLDL, very low density lipoprotein; Igf2, 
insulin-like growth factor 2; LC-MS, liquid chromatography-mass spectrometry; TLC, thin 
layer chromatography; HE, hemotoxylin / eosin; DCF, 2’,7’-dichlorofluorescein; TG, 
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triglyceride; FFA, free fatty acid; CH, cholesterol; CE, ceramide; PE, 
phosphatidylethanolamine; PC, phosphatidylcholine; PS, phosphatidylserine; LPC, 
lysophosphatidylcholine; DG, diglyceride. 
 
Core tip 
We describe a new method to quantify lipid classes in steatosis/steatohepatitis having 
advantages over both histology and classical analytical methods. Since lipid classes exert 
differential pathophysiological actions our method should be of interest for all researchers 
dealing with mechanisms of steatosis and steatohepatitis. 
We employ our method to investigate the lipid profile in the steatosis p62 transgenic mouse 
model. p62 was originally identified as an autoantigen overexpressed in hepatocellular 
carcinoma patients, its expression correlates with poor prognosis, and it induces steatosis. The 
interesting lipid profile in p62 transgenic animals suggests that it might advance the step from 
steatosis towards steatohepatitis. 
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2.1.4 Introduction 
The incidence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis 
(NASH) has dramatically increased in Western countries during the last decades[1-3]. Still, the 
diagnosis of NAFLD displays a problem since there is a known heterogeneity in the 
histological staging of lipid accumulation in the liver[4, 5]. This problem is equally relevant for 
research laboratories studying mechanistic and therapeutic aspects of NAFLD and NASH. 
A commonly used model for the investigation of NASH is the methionine choline deficient 
(MCD) mouse model, which is histologically similar to human NASH regarding 
steatohepatitis and fibrosis[6]. The MCD model is well characterized regarding its effect on the 
expression of lipid regulators, such as lipogenic transcription factors and lipogenic enzymes[7, 
8]
. The development of steatosis in the MCD model is attributable in part to impaired very low 
density lipoprotein (VLDL) secretion due to the deficiency of methionine and choline, which 
are the precursors for phosphatidylcholine, the main phospholipid coating VLDL particles[9].  
 An interesting but as yet less characterized steatosis model is the insulin-like growth factor 2 
(Igf2) mRNA binding protein p62/IMP2-2/IGF2BP2-2 transgenic mouse model[10]. p62 was 
originally identified as an autoantigen in an HCC patient[11] and its expression correlates with 
poor prognosis in HCC[12]. Hepatic p62 overexpression induces a microvesicular fatty liver 
[10]
, which is characterized by an absence of inflammatory processes and liver damage[10]. Still 
p62 overexpression amplifies murine NASH and fibrosis[13]. 
 NAFLD, even in the absence of cirrhosis, can progress to hepatocellular carcinoma (HCC)[14]. 
Increasing knowledge suggests that not only the increase in lipid accumulation itself but 
rather the hepatic lipid composition plays a dominant role in the development of both simple 
steatosis and steatohepatitis[15]. Lipid composition has in fact been shown to have a 
pathophysiological relevance in different metabolic diseases[15-18] as well as in cancer[19]. 
Accordingly, the pharmacologically reduced production of cholesterol by inhibition of 
hydroxy-methyl-glutaryl-coenzyme A reductase is discussed as a strategy for the 
chemoprevention and a slower progression of HCC[20]. The comparison of the lipidome of a 
murine NASH and HCC model with the human NASH and HCC lipidome found significant 
changes within several fatty acid signatures between the normal, NASH, and HCC 
lipidome[21]. Therefore, a more comprehensive characterization and understanding of 
pathophysiological lipidomic changes in liver diseases and common disease models seems 
mandatory. 
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 For the investigation of lipid composition liquid chromatography–mass spectrometry (LC-
MS) is state-of-the-art. However, due to high costs for the equipment and maintenance, the 
method is not suitable for routine analyses in clinical and research laboratories. Furthermore, 
the results obtained by LC-MS contain information in a level of detail too complex for most 
of the studies, in which rather general alterations in lipid classes are of interest. Thin layer 
chromatography (TLC) offers some advantages over LC-MS. For example, the possibility to 
apply many different samples on a single TLC plate is in practice often faster than LC[22]. 3D 
TLC was developed in the 1960s as a reliable method for lipid separation. However, a major 
limitation of the technique is the fact that it is possible to test only one sample per plate[23]. 
Since 3D TLC has a very low inter-plate reproducibility it is only suitable for qualitative 
measurements.  
We herein present a rapid and low-cost quantitative 1D TLC, which can detect major lipid 
classes and can be used to quantitatively compare up to 12 samples per plate. Furthermore, we 
provide insight into changes of lipid composition in the p62 transgenic mouse model for the 
first time[13].  
 
2.1.5 Materials and Methods 
Materials  
Standard substances 1,3-diolein (D3627), L-α-lysophosphatidylcholine from egg yolk 
(L4129), cholesterol (C8667), glyceryl trioleate (T7140), 3-sn-phosphatidylethanolamine 
from bovine brain (P7693), L-α-phosphatidylcholine (P3556), 1,2-diacyl-sn-glycero-3-
phospho-L-serine (P7769), non-hydroxy fatty acid ceramide from bovine brain (C2137), and 
stearic acid (85679) were purchased from Sigma-Aldrich (Taufkirchen, Germany). The 
standard substances were dissolved in chloroform/methanol (1:1 [v/v]) at a concentration of 1 
mg/ml, aliquoted, and stored at -80°C. TLC silica gel 60 F254 glass plates were purchased 
from Merck (105715, Merck, Darmstadt, Germany). All solvents were distilled prior to 
utilization.  
 
Animal models 
All animal procedures were performed in accordance with the local animal welfare 
committee. Mice were kept under stable conditions regarding temperature, humidity, food 
delivery, and 12 h day/night rhythm.  
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Steatosis model 
p62 transgenic mice were established as described previously[10]. Mice carrying a liver 
enriched activator protein promoter under tetracycline transactivator control[24] were crossed 
with p62 transgenic mice, in which the human p62 is under the control of the transrepressive 
responsive element cytomegaly virus (TRE-CMVmin). The double positive offspring expresses 
p62 liver-specifically. The mice were sacrificed at an age between 2.5 and 5 weeks. 
 
Steatohepatitis model 
Wild-type mice were fed either a methionine choline deficient (MCD, 960439, MP 
Biomedicals, Illkirch Cedex, France) or a methionine choline supplemented control diet (co, 
960441, MP Biomedicals, Illkirch Cedex, France) for 3 weeks.  
 
Histology 
For hematoxylin / eosin (HE) staining 5 µm paraffin slides were rehydrated in a xylol/alcohol 
series, incubated for 10 min in hematoxylin, washed for 5 min under running water, and 
incubated for 2 min in eosin.  
 
Extraction of bovine and murine liver lipids 
Bovine liver was bought from a local butchery and directly freeze dried and stored at -80°C. 
Lipids from snap-frozen murine or bovine liver samples were extracted by a modified version 
of a published method[25]. Briefly, 60 mg liver samples were lyophilized, 15 mg of the freeze-
dried tissue was dispersed with 18 volumes of a mixture of hexane / 2-propanol (3:2 [v/v]) for 
10 minutes, and centrifuged at 4°C and 10,000 g for 10 minutes. The supernatant was 
transferred to a new vial and dried under a nitrogen stream, redissolved in an appropriate 
volume of chloroform / methanol (1:1 [v/v]), and applied in equal amounts onto the TLC 
plates. 
 
1D TLC with two solvent system 
The TLC plates were prewashed with a mixture of chloroform / methanol (2:1 [v/v]) to 
remove any contaminants and afterwards activated at 110°C for 1 hour. The samples and 
standard substances were applied onto the TLC plates and chromatographically separated 
with the first solvent system containing chloroform / methanol / acetic acid / water (50:30:8:3 
[v/v/v/v])[26] to half of the plate. The TLC was dried and subjected to chromatography in a 
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second solvent system consisting of heptane / diethyl ether / acetic acid (70:30:2 [v/v/v])[27] to 
the top of the plate[28]. 
 
Detection and quantification 
The TLC plates were dried for 30 minutes under a nitrogen stream and first sprayed with 
0.1% 2’,7’-dichlorofluorescein (DCF, 109676, Merck, Darmstadt, Germany) in methanol and 
afterwards with sulfuric acid / ethanol (1:1 [v/v]) followed by heating at 160 °C[23]. After 
drying the plates one UV image at 312 nm for DCF and one white top light image for sulfuric 
acid / ethanol was captured using the Biostep (Jahnsdorf, Germany) dark hood dh-4050 with 
transilluminator Biostep bioview (excitation 312 nm, UST-20M-8E) and an stationary fixed 
olympus digital camera (Hamburg, Germany) in combination with the Biostep argus X1 
software (version 4.1.10). The unprocessed images in tiff format were quantified using the 
ImageJ 1.47i software[29]. 
 
Statistical analysis 
Results are expressed as means +/- SE. The statistical significance was determined by 
independent two-sample t-test and was considered as statistically significant when p values 
were less than 0.05. The Microsoft® Office Excel 2003 software (Microsoft Coperation, 
Redmond, USA) was used for statistical analyses.  
 
2.1.6 Results 
Quantification of lipids on the TLC plate 
In order to check the linearity of the method used, lipid standards for triglyceride (TG), free 
fatty acid (FFA), cholesterol (CH), ceramide (CE), phosphatidylethanolamine (PE), 
phosphatidylcholine (PC), phosphatidylserine (PS), lysophosphatidylcholine (LPC), and 
diglyceride (DG) (2.5, 5, 7.5, 10, 12.5, 15, 20 µg, each) were chromatographed, stained, and 
quantified according to our newly developed method described in the methods section. The 
DCF spray reagent was susceptible to all subjected lipids, the sulfuric acid / ethanol spray 
reagent was susceptible to almost all substances except for the FFA stearic acid and LPC 
(Figure 1A). As expected the band intensities increased with higher amount of the standard 
substances (Figure 1A). The quantification revealed a strong correlation with R2 values close 
to one for all substances (Figure 1B). 
  Publication I 
 20
 
 
Figure 1 Quantification of lipids on the TLC plate. (A) Representative lipid dilution series 
(range: 2.5, 5, 7.5, 10, 12.5, 15, 20 µg) detected with DCF or sulfuric acid / ethanol. (B) 
Quantification of the standard dilution series detected with DCF or sulfuric acid / ethanol and 
quantified with ImageJ. Results represent the mean ± SE from at least two independent TLC 
plates. FFA: free fatty acids. 
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Validation of the lipid extraction procedure 
For validation of the reproducibility of the extraction procedure, freeze-dried tissue from 
bovine liver was extracted in seven independent extraction procedures and subjected to 
chromatography. The extraction procedure revealed a high reproducibility in all lipid classes 
investigated (Figure 2A, B). PC, PE, TG and CH were most prominent in bovine liver (Figure 
2A, B).  
 
 
Figure 2 Validation of the lipid extraction procedure. (A) Freeze-dried bovine liver was 
extracted in seven independent extraction procedures (E1-E7). STA: standard substances co-
chromatographed with the samples. left: detection with DCF; right: detection with sulfuric 
acid / ethanol. (B) Quantification of TLC with ImageJ detected with DCF (left) or sulfuric 
acid / ethanol (right).  
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Lipid quantification in different mouse models 
Steatohepatitis / MCD mouse model 
In order to test whether altered lipid composition can be determined reliably we used a well 
established murine steatohepatitis model, for which altered lipid classes are known[30]. Livers 
from control and MCD fed mice were processed, extracted, and lipids were chromatographed 
and detected as mentioned above. Two independent TLC plates revealed a strong increase in 
TG with DCF and sulfuric acid / ethanol (Figure 3B, C). As the MCD model is characterized 
by choline deficiency, the levels of PC were significantly decreased, whereas the levels of PE 
were significantly increased (Figure 3B, C). We consequently observed a reduced PC/PE ratio 
by approximately one third (p = 0.003) with both detection methods. The other lipid classes 
investigated were not significantly changed (data not shown). Due to the high amount of TG 
in this model, the routinely subjected amount of lipid extract had to be reduced by five folds 
compared to normal tissues. Routinely used amounts led to overloading of the plates (data not 
shown). 
 
Steatosis / p62 transgenic mouse model 
Since our method confirmed changes in lipid classes in the MCD steatohepatitis mouse 
model, we used it to characterize changes in lipid classes in the p62 steatosis model. The 
model shows distinct histologically proven microvesicular lipid incorporation in up to 58% of 
the animals[10] when specific lipid staining is performed. Accordingly, HE staining revealed a 
milder extent of steatosis compared to the MCD diet (Figure 3A, D). Two independent TLC 
plates revealed that all detected lipid classes were significantly increased in the livers of p62 
transgenic animals (Figure 3E, F). FFA, DG and LPC were not detectable (Figure 3E). The 
strongest effect was observed for TG, which were increased approximately two folds in p62 
trangenic animals compared to wildtype controls (Figure 3F). Interestingly, although the 
levels of both PC and PE were significantly increased, the PC/PE ratio was significantly 
decreased by about 10% (p = 0.05) with both detection methods. The same was true for the 
ratio of CH/PC, which was increased by approximately 23%, as validated by the DCF 
detection (p = 0.05). 
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Figure 3 Lipid quantification in different mouse models. (A) Representative HE staining 
of control (co) or MCD fed mice (200x). (B) Representative TLC detected with DCF (left) or 
sulfuric acid / ethanol (right). (C) Quantification of TLC with ImageJ, detected with DCF 
(left) or sulfuric acid / ethanol (right). Results represent the mean ± SE from at least two 
independent TLC plates with n = 7 in each group. (D) representative HE staining of wildtype 
(wt) and p62 transgenic mice (p62 tg)(200x). (E) Representative TLC detected with DCF 
(left) or sulfuric acid / ethanol (right). (F) Quantification of TLC with ImageJ detected with 
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DCF (left) or sulfuric acid / ethanol (right). Results represent the mean ± SE from at least two 
independent TLC plates and n = 4 in each group.  
 
2.1.7 Discussion 
Within this work we developed a rapid analytical method, which allows to quantify changes 
in hepatic lipid classes. The newly established method confirmed published findings for the 
lipid changes in a mouse NASH model and for the first time reports the lipid composition in 
the p62 transgenic steatosis model. 
 
TLC method 
The one-dimensional TLC with a two-step solvent system and the detection with DCF or 
sulfuric acid / ethanol was able to separate and to detect the major lipid classes of TG, FFA, 
CH, CE, PE, PC, PS, LPC, and DG within a time period of 2.5 h (Figure 4). Standard curves 
revealed a high linearity of the standard substances from 2.5 to 20 µg. The chosen standard 
substances corresponded with the major lipid classes typically changed in NAFLD/NASH[31]. 
A lack of reactivity of saturated fatty acids towards a sulfuric acid / ethanol / hexane reagent 
was reported previously[32] and is in line with our finding that our FFA (the saturated fatty 
acid stearic acid) and LPC standard (which contains mostly palmitic acid and stearic acid) 
showed no staining with sulfuric acid / ethanol. 
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Figure 4 TLC method. Samples were freeze-dried, extracted, centrifuged, and the 
supernatant was transferred to a new vessel and dried under gaseous nitrogen. In the 
meantime plates were prewashed and activated. Standard solutions and samples were 
subjected to the prewashed and activated TLC plates and developed with the first eluant 
system to half of the plate. After drying the TLC plate was subjected to a second eluant 
system in the same direction up to the top of the plate. After drying of the plates, lipids were 
visualised with DCF and afterwards with sulfuric acid / ethanol and heating to 160°C.  
 
Most publications only investigate an assortment of the most important lipids in liver 
diseases[18, 26, 27, 31]. It is almost impossible to detect all abundant lipid species in tissues within 
one method, because the physicochemical properties of the broad spectrum of lipid classes are 
too variable[22]. The lipid class spectrum of the bovine liver extract was quite similar to 
published studies, which showed that PC and PE are the main components of the bovine liver 
phospholipids[34, 35].  
The extraction procedure has the advantage to be quick and that it requires relatively low 
amounts of tissue (approximately 70 mg wet weight tissue) compared to other methods[33]. 
Additional advantages are a low contamination with non-lipids due to the high apolarity of the 
solvent mixture, a low toxicity, a low phospholipid degradation, and the possibility to use 
plastic materials[22, 36]. Freeze-drying of the liver tissue samples reduces the enzymatic activity 
of potential lipid degrading enzymes[37]. Taken together, this method is an easy, cheap, and 
rapid screening method for up to 12 samples in parallel. In addition, it needs only little 
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technical equipment. The TLC method allows detection from the applied crude lipid extracts 
without the need of additional purification steps. 
 
Confirmation of known changes in lipid classes in the MCD NASH model 
After establishing a reliable technique we sought to confirm known alterations in lipid classes 
in the MCD NASH model. The MCD-induced NASH has the advantage of a histological 
appearance highly similar to human NASH concerning steatosis, i.e. mixed inflammatory cell 
infiltrates, hepatocellular necrosis, and eventual pericellular fibrosis mimics[38]. We found 
strongly increased levels of TG, increased levels of PE, and decreased levels of PC, which led 
to a significantly decreased PC/PE ratio. Yao et al. reported decreased PC levels in choline 
deficient rat hepatocytes[39]. Since PC biosynthesis is partly due to the methylation of PE by 
S-adenosyl methionine[40], it is not surprising that the lack of methionine in this model 
resulted in the accumulation of PE. An increase in TG[30] and a decreased mitochondrial 
PC/PE ratio[41] in the MCD diet was described previously. Therefore, our one-dimensional 
TLC method could well confirm known alterations in lipid classes in this dietary model of 
NASH. 
 
Lipid composition in p62-induced steatosis 
This is the first study, which clarifies the lipid composition in p62-induced steatosis. The 
increase in all detected lipid classes might be due to a p62-mediated activation of lipogenic 
genes induced by the lipogenic growth factor Igf2[42], which is highly overexpressed in p62 
transgenic animals[10]. The p62-induced microvesicular steatosis is difficult to evaluate with 
simple histological H/E staining (Figure 3D). Still, our TLC method revealed strongly 
affected lipid accumulation also in histologically normal tissue and allows more reliable and 
quantitative statements.  
Accumulation of TG in hepatocytes is a hallmark of NAFLD[43]. As expected, TG were the 
lipid class elevated to the highest degree in p62-induced fatty liver. Interestingly, Yetukuri et 
al. described a positive correlation between TG and CER in an ob/ob steatosis model[44]. The 
precursor for TG[45], namely DG, were not detectable in our murine models, despite the fact 
that DG standard series revealed strong signals. A similar observation could be seen for FFA 
and LPC. Since the age of our investigated transgenic and control animals were 2.5 to 5 
weeks, the lack of abundance of some lipid species might be explained by the relatively 
young age. In this context Rappley et al. reported age-dependent changes in phospholipid 
levels in mouse brain[46].  
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An unaltered content of FFA in human NAFLD was described previously[18]. Since we saw 
weak signals for FFA, which were not elevated in the p62 transgenics, no elevation by p62 
can be assumed. 
One of the most complex investigations of the human NAFLD/NASH lipidome found in the 
literature reports elevated CH levels, and an increased ratio of CH to PC[18]. Accordingly, 
these results are in line with the findings in our p62 steatotic animals. On the other hand, the 
literature report also found decreased levels of PC and PE, whereas PS remained unaltered[18]. 
Since increased CH levels are often associated with enhanced PC synthesis[47], increased PC 
levels in our p62 transgenic animals might be explainable. Most notably, a decreased PC/PE 
ratio was observable in p62 transgenic animals although PC and PE levels were both 
increased. The distinct manipulation of the PC/PE ratio performed by Li et al. showed that an 
elevation of the ratio can in fact reverse steatohepatitis, but not steatosis[48]. This observation 
strongly suggests that a decreased PC/PE ratio plays a role in the progression from steatosis to 
steatohepatitis. In fact, NASH patients were found to have decreased PC/PE ratios in the same 
study[48]. The responsible mechanisms are as yet only speculative and might involve the 
inhibition of the PE N-methyltransferase[48], which converts PE to PC. Among the lipids, 
which were elevated in the p62 transgenics, cholesterol[49] and ceramides[50]are highly 
cytotoxic. Although p62 overexpression induces a benign steatosis in the absence of 
inflammatory events, we speculate that the increased levels of CH and CER and the decreased 
PC/PE ratio might finally promote an inflammatory environment in the livers of p62 
transgenic animals. In fact, p62 overexpression can promote the development of NASH and 
fibrosis[13]. 
Taken together, we have established a rapid technique to quantify altered lipid classes in 
experimental models of steatosis and steatohepatitis. The method confirmed known changes 
in the well-established MCD NASH model and for the first time revealed a distinctly altered 
lipid composition in the p62 steatosis model. The knowledge of changes in lipid composition 
might be helpful for the understanding of pathophysiological mechanisms in NAFLD and 
NASH. 
 
2.1.8 Comments 
1 Background 
Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis are mostly of benign 
appearance, but they are highly discussed as potential risk factors for the development of 
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hepatocellular carcinoma. Hepatocellular carcinoma is a highly aggressive cancer type with 
high mortality, which is difficult to detect and to cure. Changes in lipid and fatty acid 
composition in disease progression to hepatocellular carcinoma are not well characterized, but 
are suggested to be of major importance. The high impact of these lipidomic changes needs 
appropriate in vivo models, and rapid and reliable methods to quantify the whole spectrum of 
lipid classes simultaneously. 
 
2 Research frontiers 
A state of the art method used for the identification of lipid classes is lipid chromatography 
coupled with mass spectrometric detection. This method is highly cost intensive, needs a lot 
of time for the establishment of the method and requires well-educated and experienced staff. 
Thin layer chromatography on the other hand represents a well-established technique, which 
allows a fast establishment in each laboratory within a really short time and allows a highly 
sensitive detection. As already mentioned, the lipidomic changes in the different states of 
liver disease progression in diverse in vivo mouse models and their potential correlation with 
human liver diseases are rare. 
 
3 Related publications 
Simon Y, Kessler SM, Bohle RM, Haybaeck J, Kiemer AK. The insulin-like growth factor 2 
(IGF2) mRNA binding protein p62/IGF2BP2-2 as a promoter of NAFLD and HCC? Gut 
2014; 63, 861-863. 
Kessler SM, Pokorny J, Zimmer V, Laggai S, Lammert F, Bohle RM, Kiemer AK. IGF2 
mRNA binding protein p62/IMP2-2 in hepatocellular carcinoma: antiapoptotic action is 
independent of IGF2/PI3K signaling. Am J Physiol Gastrointest Liver Physiol 2013; 304(4): 
G328-G336 doi: 10.1152/ajpgi.00005.2012 PMID: 23257922 
Laggai S, Kessler SM, Gemperlein K, Haybaeck J, Mueller R, Kiemer AK. 1270 Altered fatty 
acid profile in livers overexpressing the Igf2 mRNA binding protein p62: Induction of fatty 
acid elongase ELOVL6 via Igf2-dependent SREBP1 activation. J  Hepatol 2013; 58: S514 
PMID: S0168-8278(13)61271-4 
Bell JL, Wachter K, Muhleck B, Pazaitis N, Kohn M, Lederer M, Huttelmaier S. Insulin-like 
growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer 
progression? Cell Mol Life Sci 2013; 70(15): 2657-2675 doi: 10.1007/s00018-012-1186-z 
PMID: 23069990 
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Tybl E, Shi FD, Kessler SM, Tierling S, Walter J, Bohle RM, Wieland S, Zhang J, Tan EM, 
Kiemer AK. Overexpression of the IGF2-mRNA binding protein p62 in transgenic mice 
induces a steatotic phenotype. J Hepatol 2011; 54(5): 994-1001 doi: S0168-8278(10)00944-
X PMID: 21145819 
 
4 Innovations and breakthroughs 
The thin layer chromatography of lipids is normally limited by the requirement to separately 
analyze either polar lipids or neutral lipids, each on one plate. Another method is the 3D thin 
layer chromatography, which allows only one sample per plate. Here we describe a fast 
screening method to chromatograph several samples on one plate, to separate the main polar 
and neutral lipid classes, to visualize them by two different staining methods, and to quantify 
them using the freely available ImageJ software within a short time. We proved the reliability 
of the method by comparing the obtained data from a methionine choline deficient non-
alcoholic steatohepatitis mouse model to published data. We investigated the alterations in 
lipid classes in the p62/IMP2-2/IGF2BP2-2 transgenic mouse model for the first time and 
found interesting changes, which might indicate the progressive character of this steatosis 
model. 
 
5 Applications 
The described method can be used by all research laboratories for the lipidomic analyses of 
liver samples from the whole array of existing and newly developed experimental models for 
liver diseases. The method is not restricted to steatosis and steatohepatitis, but should also be 
useful for the analysis of HCC samples. While the gold standard for lipidomic analyses, i.e. 
lipid chromatography-mass spectrometry is a quite expensive method, the thin layer 
chromatographic method can also be used in laboratories, which have no access to respective 
high-end equipment. The p62 transgenic mouse model might be a potentially interesting 
model to investigate mechanisms of steatosis and disease progression. Further 
characterization and correlation to human data might help to understand the role of lipid 
changes in pathogenesis. 
 
6 Terminology  
Non-alcoholic fatty liver disease: non-alcoholic fatty liver disease is characterized by a strong 
accumulation of lipids, especially triglycerides, within hepatocytes; non-alcoholic 
steatohepatitis: non-alcoholic steatohepatitis is a steatotic liver, which is characterized by an 
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inflammatory environment and might result in fibrosis; hepatocellular carcinoma: 
hepatocellular carcinoma is an aggressive form of liver cancer; thin layer chromatography: 
thin layer chromatography is a chromatographic method, glass or aluminium plates are coated 
mostly with silica gel and allows separation with different solvent systems. 
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2.2 The IGF2 mRNA binding protein p62/IGF2BP2-2 induces 
fatty acid elongation as a critical feature of steatosis 
 
      II 
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Since the quantity of hepatic lipids was icreased (Tybl et al., 2011) and also the quality of 
hepatic lipids was altered in the livers of p62 transgenic animals (Laggai et al., 2013), the aim 
of this study was to evaluate changes in the fatty acid profile (incorporated in total lipids), to 
decipher the pathways related to p62-induced steatosis development and to validate these 
pathways also in the human system. 
 
The IGF2 mRNA binding protein p62/IGF2BP2-2 induces fatty acid elongation as a 
critical feature of steatosis 
Stephan Laggai, Sonja M Kessler, Stefan Boettcher,Valérie Lebrun, Katja Gemperlein, Eva 
Lederer, Isabelle A Leclercq, Rolf Mueller, Rolf W Hartmann, Johannes Haybaeck and 
Alexandra K Kiemer. 
 
This research was originally published in Journal of Lipid Research. Laggai, S., Kessler, 
S.M., Boettcher, S., Lebrun, V., Gemperlein, K., Lederer, E., Leclercq, I.A., Mueller, R., 
Hartmann, R.W., Haybaeck, J., and Kiemer, A.K. The IGF2 mRNA binding protein 
p62/IGF2BP2-2 induces fatty acid elongation as a critical feature of steatosis. J Lipid Res. 
2014; 55: 1087-1097. doi: 10.1194/jlr.M045500. Copyright © 2014, the American Society for 
Biochemistry and Molecular Biology, Inc. 
 
The full text article can also be found at: 
http://www.jlr.org/content/55/6/1087.full 
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2.2.2 Title page 
 
The IGF2 mRNA binding protein p62/IGF2BP2-2 induces fatty acid 
elongation as a critical feature of steatosis 
Stephan Laggaia, Sonja M. Kesslera, b, c, Stefan Boettcherd, Valérie Lebrunc, Katja 
Gemperleine,f, Eva Ledererb, Isabelle A. Leclercqc, Rolf Muellere,f, Rolf W. Hartmannd,f, 
Johannes Haybaeckb, Alexandra K. Kiemera* 
 
aDepartment of Pharmacy, Pharmaceutical Biology, Saarland University, Saarbrücken, 
Germany 
bInstitute of Pathology, Medical University of Graz, Graz, Austria 
cLaboratory of Hepato-gastroenterology, Institut de Recherche expérimentale et Clinique, 
Université catholique de Louvain, Brussels, Belgium 
dDepartment of Pharmacy, Pharmaceutical and Medicinal Chemistry, Saarland University, 
Saarbrücken, Germany 
eDepartment of Pharmacy, Pharmaceutical Biotechnology, Saarland University, Saarbrücken, 
Germany 
fHelmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for 
Infection Research (HZI), Saarbrücken, Germany 
 
*Corresponding Author 
Telephone: +49-681-302-57301  
Fax: +49-681-302-57302 
Email: pharm.bio.kiemer@mx.uni-saarland.de 
 
Running title: p62 induces fatty acid elongation 
Abbreviations: acetyl-CoA carboxylase alpha (ACC/ACACA), carbohydrate responsive 
element-binding protein (CHREBP/MLXIPL), carnitine palmitoyltransferase 1A (CPT1A), 
ELOVL fatty acid elongase 6 (ELOVL6), fatty acid synthase (FASN), gas chromatography-
mass spectrometry (GC-MS), glucose infusion rate (GIR), glucose turnover (TO), hepatic 
glucose production (HGP), hepatocellular carcinoma (HCC), insulin-like growth factor 2 
(IGF2), liver-X-receptor alpha (LXR-α/NR1H3), non-alcoholic fatty liver disease (NAFLD), 
non-alcoholic steatohepatitis (NASH), peroxisome proliferator-activated receptor alpha 
(PPARA), pyruvate kinase, liver and RBC (L-PK, PKLR), sterol regulatory element binding 
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transcription factor 1 (SREBF1/SREBP1), ultra high-performance liquid chromatography–
mass spectrometry (UHPLC-MS/MS) 
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2.2.3 Abstract 
Liver-specific overexpression of the insulin-like growth factor 2 (IGF2) mRNA binding 
protein p62/IGF2BP2-2 induces a fatty liver, which highly expresses IGF2. Since IGF2 
expression is elevated in patients with steatohepatitis, the aim of our study was to elucidate 
the role and interconnection of p62 and IGF2 in lipid metabolism. Expression of p62 and 
IGF2 highly correlated in human liver disease. p62 induced an elevated ratio of C18:C16 and 
increased ELOVL fatty acid elongase 6 (ELOVL6) protein, the enzyme catalyzing the 
elongation of C16 to C18 fatty acids and promoting non-alcoholic steatohepatitis in mice and 
humans. p62 overexpression induced the activation of the ELOVL6 transcriptional activator 
SREBF1. Recombinant IGF2 induced the nuclear translocation of sterol regulatory element 
binding transcription factor 1 (SREBF1) and a neutralizing IGF2 antibody reduced ELOVL6 
and mature SREBF1 protein levels. Concordantly, p62 and IGF2 correlated with ELOVL6 in 
human livers. Decreased palmitoyl-CoA levels as found in p62 tg livers can explain the 
lipogenic action of ELOVL6. Accordingly, p62 represents an inducer of hepatic C18 fatty 
acid production via a SREBF1-dependent induction of ELOVL6. These findings underline the 
detrimental role of p62 in liver disease.  
Supplemental Keywords: ELOVL6, p62/IGF2BP2-2/Imp2-2, SREBF1/SREBP1, IGF2 
signalling, Hepatic steatosis 
 
 
  Publication II 
 41
2.2.4 Introduction 
Non-alcoholic fatty liver disease (NAFLD) is considered as the most common liver disorder 
in Western countries with a prevalence of 20-30% of the adult population (1, 2). There is a 
strong correlation between characteristics of the metabolic syndrome, such as obesity and 
diabetes mellitus, and NAFLD/non-alcoholic steatohepatitis (NASH) (3). 
The ‘two-hit’ hypothesis represents a common model to describe the development and 
progression of fatty liver diseases. A simple steatosis can stand for the first step in early liver 
pathogenesis (4, 5). The progression from simple steatosis to NASH requires a ‘second hit’ 
mediated by reactive oxygen species and release of inflammatory cytokines (6). This 
inflammatory environment can result in hepatic cirrhosis and finally in hepatocellular 
carcinoma (HCC) (7). 
The development of hepatosteatosis can be induced by different mechanisms. The synthesis 
of lipids is regulated in a complex interplay induced by a set of lipogenic transcription factors, 
among which liver-X-receptor alpha (LXR-α, NR1H3), sterol regulatory element binding 
transcription factor 1 (SREBF1, SREBP1), and carbohydrate responsive element-binding 
protein (ChREBP, MLXIPL) represent the most important ones (8). In this context, the fact 
that MLXIPL controls 50% of hepatic lipogenesis by regulating glycolytic and lipogenic gene 
expression (9) illustrates the importance of both insulin- as well as glucose-induced lipogenic 
pathways. One of the relevant inducers of lipid degradation in the liver is the peroxisome 
proliferator-activated receptor alpha (PPARA) (10). Most importantly, there is a close 
interconnection between catabolic and anabolic pathways. In this context it is important to 
note that the mitochondrial β-oxidation pathway is negatively regulated by high malonyl-CoA 
levels (11, 12).  
Besides the amount of lipids, which are relevant for pathophysiological actions, there is 
increasing evidence that also the composition of lipids has an impact on pathophysiology. In 
fact, human NAFLD is characterized by numerous changes in hepatic lipid composition and 
relative abundance of specific fatty acids (13, 14). Also hepatitis (B/C) has been described to 
strongly alter hepatic lipid content and composition (15, 16). Recently, the fatty acid elongase 
6 (ELOVL6), which catalyzes the elongation of C16 to C18 fatty acids (17) and is a direct 
target of SREBF1 (18, 19), has been shown to promote NASH in mice and humans and to be 
overexpressed in a murine NASH model (20, 21). Interestingly, however, there is still a lack 
of understanding of the upstream signaling pathways being responsible for SREBF1 
activation and why elevated ELOVL6 increases total fatty acid production. Also the role of 
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ELOVL6 in HCC is as yet poorly understood and seems to depend on disease etiology (21-
23). 
We recently reported that a liver-specific overexpression of the insulin-like growth factor 2 
(IGF2) mRNA binding protein p62/IGF2BP2-2 induces steatosis in mice, coupled with high 
Igf2 expression and activation of the phosphoinositide 3-kinase/AKT-signaling pathway (24). 
Furthermore, p62 has been shown to promote NASH development (25). Most lipid species are 
elevated in p62-induced steatosis, with triglycerides showing the strongest increase (26). p62 
was originally identified as an autoantigen overexpressed in about one third to two thirds of 
HCC patients and correlates with poor outcome (27-30). Interestingly, also IGF2 is 
overexpressed in NASH and HCC (31, 32), which is linked to p62 overexpression in HCC 
(27), and might be explained by the involvement of the IGF2 mRNA-binding proteins in 
RNA localization, stability and translation (33). p62 is a splice variant of IGF2BP2 lacking 
exon 10, though exon 10 deletion is not affecting the six characteristic RNA binding motifs 
(33). Recently, Li et al. reported IGF2BP2 to bind and control the translation of c-Myc, Sp1 
transcription factor and insulin-like growth factor 1 receptor (34). Binding affinities of 
IGF2BP2-2 to the respective mRNAs, however, are not described in the literature. 
Aim of our study was to decipher the effects of p62 on lipid metabolism and to elucidate the 
influence of IGF2. 
 
2.2.5 Materials and Methods 
Animals 
All animal procedures were performed in accordance with the local animal welfare 
committee. Mice were kept under stable conditions regarding temperature, humidity, food 
delivery, and 12 h day/night rhythm. p62 transgenic mice were established as described by 
Tybl et al. (24). The mice were sacrificed at an age between 2.5 and 5 weeks. 
 
Hyperinsulinemic euglycemic clamp study 
Hepatic insulin sensitivity was determined by the hyperinsulinemic euglycemic clamp 
technique as described previously (35). 
 
Human liver tissue 
35 human liver tissues from patients undergoing surgical resection were analysed in the 
framework of the project, which was authorized by the ethical committees of the Medical 
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University of Graz (Ref. Nr. 1.0 24/11/2008) and the University of Heidelberg (Prof. 
Bannasch). Details on patient data are given in supplemental data Table I (online).  
 
Cell culture and transfection 
HepG2 cells were cultured in RPMI-1640 (PAA, Cölbe, Germany) with supplementation of 
10% [v/v] FCS (PAA, Cölbe, Germany), 1% [v/v] glutamine (PAA, Cölbe, Germany), and 
1% [v/v] penicillin/streptomycin (PAA, Cölbe, Germany)
 
at 37°C and 5% CO2. HepG2 
overexpression and knockdown assays were performed according to Kessler et al. (27). For 
the detection of IGF2-mediated SREBF1 translocation, cells were treated for the indicated 
time with rhIGF-II (0.075 µg/ml, 292-G2, R&D Systems, Minneapolis, U.S.A) or with IGF2 
antibody (ab9574, Abcam, United Kingdom) as previously described (27). 
 
Fatty acid measurement by gas chromatography-mass spectrometry (GC-MS) 
Murine liver samples or HepG2 cells were lyophilized, hydrolyzed by the fatty acid methyl 
ester (FAME) method and analysed according to Bode et al. (36). Methyl-nonadecanoate 
(74208, Sigma Aldrich, Taufkirchen, Germany) was used as an internal standard. The method 
detects both free and bound free fatty acids. 
 
Histochemistry 
Hematoxylin / eosin (HE)-staining and immunohistochemical detection of F4/80 of paraffin 
embedded sections were performed as previously reported (22, 24). 
 
Real-time RT-PCR 
Isolation of total RNA and reverse transcription was performed as described previously (37). 
RNA from human liver samples was isolated as previously described (27). Real-time RT-PCR 
was performed in an iQ5 cycler (Bio-Rad, Munich, Germany) or in a CFX96 cycler (Bio-Rad, 
Munich, Germany) with 5 x HOT FIREPol® EvaGreen® qPCR Mix Plus (Solis BioDyne, 
Tartu, Estonia). All samples were estimated in triplicate. Primers and conditions are listed in 
supplemental data Table II. Efficiency was determined for each experiment using a cDNA 
dilution series with a starting concentration equivalent to 0.5 µg RNA or with a standard 
dilution series as described previously (37). The relative gene expression was normalized to 
ACTB or 18s mRNA values. 
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Preparation of nuclear extracts 
Nuclear extracts from HepG2 cells were prepared as described previously (38). 
 
Protein isolation and analysis by Western blot 
Protein isolation from murine liver tissue was done according to Tybl et al. (24), whereas 
protein isolation from cells was according to Basirico et al. (39). 
Protein separation and detection were peformed as previously described (24). Information on 
the used antibodies and conditions can be found in the supplemental data Table III. The 
primary antibodies anti-ELOVL6 and anti-α–tubulin were purchased from Sigma Aldrich 
(PRS4571, T9026, Taufkirchen, Germany), anti-SREBF1 and anti-PPARA from Abcam 
(ab3259, ab8934, Cambridge, United Kingdom), anti-FASN, anti-lamin A/C antibody from 
Cell Signaling Technology (#3180, #2032, Danvers, USA), anti-p62 antibody was kindly 
provided by Dr. Tan (TSRI, La Jolla, CA, USA) (30, 40).  
 
Palmitoyl-CoA extraction and analyses with ultra high-performance liquid 
chromatography–mass spectrometry (UHPLC-MS/MS) 
Fresh snap-frozen liver tissue was immediately freeze-dried and homogenized and stored at –
80°C. 40 mg of freeze-dried tissue was extracted for 30 minutes in 1 ml methanol containing 
n-heptadecanoyl-CoA as internal standard (with a final concentration of 500 nM in 150 µl 
final volume). The extract was centrifuged at 22,000 g for 10 min and 4°C. The supernatant 
was transferred to a new vial and dried under gaseous nitrogen and reconstituted in 150 µl 
methanol / water (1:1 [v/v]). The standard dilution series was made in methanol / water (1:1 
[v/v]). All steps were performed on ice. 
The analyses were performed using a TSQ Access Max mass spectrometer equipped with an 
ESI source and a triple quadrupole mass detector (Thermo Finnigan, San Jose, CA). The MS 
detection was carried out in heated ESI mode, at a spray voltage of 4.5 kV, a probe 
temperature of 400 °C, a nitrogen sheath gas pressure of 3.0 × 105 Pa, an auxiliary gas 
pressure of 1.0 × 105 Pa, a capillary temperature of 350 °C, and a tube lens voltage of 114 V  
in negative ionization mode. Palmitoyl coenzyme A lithium salt (P9716-5MG) and n-
heptadecanoyl coenzyme A lithium salt (H1385-5MG) were purchased from Sigma Aldrich 
(Taufkirchen, Germany). 
Xcalibur software was used for data acquisition and plotting.  
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The chromatographic separation was carried out on an Accela UPLC, consisting of a 
quaternary pump, degasser, and autosampler (Thermo Finnigan, San Jose, CA) using a 
Accucore RP-MS column (150x2.1, 2.6µm), with an injection volume of 25 µl. 
The solvent system consisted of 10 mM ammonium acetate (A) and methanol (B).  
HPLC-Method: Gradient run of initial 65% of B in A and a flow of 600 µl/min. In 0.6 min the 
solvent mixture was changed to 100% of B, with a flow of 700 µl/min and kept for 3.4 min.  
The amounts of palmitoyl-CoA and the internal standard n-heptadecanoyl-CoA were each 
determined in single reaction monitoring mode using the following transitions: 
Palmitoyl-CoA: precursor ion 1005.992 m/z; product ion 672.075 m/z; scan time 0.5 sec; scan 
width 3.000 m/z; collision voltage 44 V. 
Heptadecanoyl-CoA (ISTD): precursor ion 992.228 m/z; product ion 926.442 m/z; scan time 
0.5 sec; scan width 3.000 m/z; collision voltage 42 V. 
Palmitoyl-CoA, with a retention time of 2.27 min, was quantified using the chromatographic 
peak area relative to the internal standard (Retention time 2.17 min). The lower limit of 
quantitation was 2.1 nM. The measurement was performed with wild-type livers (n=9) and 
livers of p62 transgenic animals (n=10). Supplemental data Fig I shows the measurement of a 
representative Palmitoyl-CoA dilution series. Supplemental data Fig II (online) shows a 
representative measurement of Palmitoyl-CoA extracted from mouse liver. 
 
Statistical analysis 
Results are expressed as means ± SEM. The statistical significance was determined by 
independent two-sample t-test. Pearson’s correlation was used to test the relationship between 
p62, IGF2, ELOVL6, and FASN mRNA in human liver samples. 
The results were considered as statistically significant when p value was less than 0.05. 
 
2.2.6 Results 
Characterization of steatosis 
Liver-specific overexpression of p62 has previously been shown to induce histologically 
detectable steatotic features in about 60% of the animals (24) (Fig 1A).  
Previous data suggested no distinct inflammation in p62 transgenic animals since we observed 
no elevated liver damage (24). Still, immunohistochemical staining and real-time RT-PCR 
revealed elevated levels of the macrophage marker F4/80 in p62 transgenic livers (Fig 1B, C). 
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18.2% of p62 transgenic animals exhibited distinct leukocyte infiltrates (2-3 infiltrates per 
microscopic field, magnification 100x), which were not observed in wild-type animals. 
Our previous data indicated slightly improved glucose tolerance of p62 transgenic animals 
(24). We now performed hyperinsulinemic euglycemic clamp analysis: Both, the higher 
glucose infusion rate and lower hepatic glucose production with unchanged glucose turnover 
indicated elevated hepatic insulin sensitivity. However, these results were not statistically 
significant (Fig 1D).  
Quantification of fatty acid composition revealed that also transgenic animals, which 
exhibited a normal histology, showed an increased fatty acid content (Table 1). Still, the fatty 
acid content was even higher in animals with a histologically proven steatosis (Table 1). 
Taking all p62 transgenic animals together, we observed a 1.66 ± 0.12 fold (p = 0.0007) 
increase of the total fatty acid content compared to wild-type animals. Having a closer look at 
the composition of the fatty acids, we observed that the chain length of fatty acids was 
different in p62 transgenic livers compared to wild-type tissue: steatotic livers exhibited an 
increased ratio of C18 to C16 fatty acids (Fig 1E). 
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Fatty acid 
wt p62 tg normal histology p62 tg microvesicular steatosis 
[µg / mg dry tissue] [µg / mg dry tissue] p 
vs. wt [µg / mg dry tissue] 
p 
vs. wt 
12:0 0.05±0.05 0.26±0.13 0.205 0.81±0.18 0.0016 
14:0 0.32±0.11 0.65±0.29 0.344 2.08±0.38 0.0009 
16:0 16.7±0.77 21.82±1.99 0.050 28.72±1.75 0.00002 
16:1 0.04±0.03 0.10±0.06 0.441 0.69±0.12 0.0003 
18:0 11.7±0.20 14.04±0.71 0.018 14.24±0.54 0.0008 
18:1 5.54±0.47 9.98±1.84 0.061 19.34±1.76 0.000007 
18:2 9.75±0.62 16.69±2.49 0.035 30.12±2.76 0.00002 
20:1 n.d. 0.06±0.05 0.351 0.20±0.09 0.0455 
20:2 0.34±0.07 0.43±0.14 0.611 1.11±0.17 0.0010 
20:3 0.29±0.07 0.61±0.17 0.135 1.47±0.19 0.00006 
20:4 10.9±0.26 10.17±0.86 0.461 13.47±0.65 0.0032 
20:5 n.d. n.d.  0.08±0.08 0.3409 
22:4 0.11±0.07 0.16±0.11 0.698 0.88±0.21 0.0038 
22:5 2.20±0.92 0.98±0.64 0.340 3.31±0.66 0.3781 
22:6 1.55±0.52 1.00±0.30 0.413 0.83±0.22 0.2663 
sum FA 59.5±2.57 76.94±8.03 0.072 117.3±9.76 0.000028 
 
Table 1. p62-induced changes in murine hepatic fatty acids. Livers of wild-type (wt, n=7) 
and p62 transgenic (p62 tg, n=19, n=8 normal histology, n=11 microvesicular steatotic 
histology) mice were analyzed by GC-MS. p values indicate differences compared to values 
in livers of wt animals.  
 
In order to study the mechanisms responsible for hepatic lipid alterations we employed 
HepG2 cells, which are able to develop cellular steatosis and are frequently used for 
respective mechanistic studies (15, 41-44). The fatty acid chain length in fact depended on the 
presence of p62: when p62 was knocked down in HepG2 cells, increased levels of C16 fatty 
acids were detectable (Table 2), so that the ratio of C18 to C16 fatty acids decreased (Fig 1F). 
We therefore investigated the effect of p62 on ELOVL6, which catalyses the elongation of 
C16 to C18 fatty acids (17). 
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Fatty acid si co [µg / mg lyophilized cells] si p62 [µg / mg lyophilized cells] p 
16:0 20.06±0.91 29.21±1.93 0.03 
16:1 5.40±1.32 8.01±1.53 0.12 
18:0 8.98±1.3 10.04±1.88 0.71 
18:1 36.08±5.17 40.58±2.52 0.55 
18:2 1.63±0.21 1.31±0.25 0.57 
 
Table 2. p62-induced changes in HepG2 fatty acids. HepG2 cells treated with random 
siRNA (si co) and p62 siRNA (si p62) were analyzed by GC-MS. p values indicate 
differences compared to si co treated HepG2 cells (n=3, duplicate). 
 
We observed that ELOVL6 is induced in a p62-dependent fashion: p62 transgenic animals 
displayed significantly increased levels of ELOVL6 protein (Fig 1G). Vice versa, knockdown 
of p62 in HepG2 cells exhibited significantly reduced ELOVL6 mRNA and protein levels 
(Fig 1H). The dependency of ELOVL6 expression on p62 in human livers was supported by a 
strong correlation of p62/ELOVL6 expression (Fig 1H). 
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Figure 1. p62-induced steatosis, C18:C16 ratio, and ELOVL6 expression.  
A. HE staining of wild-type (wt) and p62 transgenic liver tissue (p62 tg) (original 
magnification 100x). 
B. F4/80 staining of wt and p62 tg liver tissue (original magnification 100x). 
C. F4/80 real-time RT-PCR of wild-type (wt) and p62 transgenic (p62 tg ) livers (n=13, each). 
D. Hyperinsulinemic euglycemic clamp study in wt (n=3) and p62 tg (n=4) mice: glucose 
infusion rate (GIR), glucose turnover (TO), and hepatic glucose production (HGP). Data show 
mean ± SEM. 
E. Hepatic C18:C16 fatty acid ratio: wt: n=10, p62 tg: n=19. 
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F. C18:C16 fatty acid ratio and Western Blot of the transfection control (72 h) in HepG2 cells 
transfected with random siRNA (si co) or p62 siRNA (si p62) (n=3, duplicate)  
G. Representative ELOVL6 Western blot of wt and p62 tg mice (n=5, each). 
H. ELOVL6 Western blot (n=3, duplicate, left) and real-time RT-PCR (n=2, triplicate, 
middle) of HepG2 transfected with si co or si p62 for ELOVL6, Right: Real-time RT-PCR for 
ELOVL6 and p62 of 35 liver tissues normalized on ACTB mRNA levels.  
 
Expression of lipogenic regulators 
Surprisingly, MLXIPL mRNA expression was significantly upregulated in p62 siRNA-treated 
HepG2 cells (Fig 2A) and downregulated in cells overexpressing p62 (Fig 2A). We could 
validate this effect in p62 tg animals, in which MLXIPL was significantly downregulated 
(15% ± 8%, p = 0.0497, n = 5 in each group). Looking at NR1H3 mRNA expression as 
another lipogenic transcription factor in either p62 overexpressing or p62 siRNA cells, we did 
not observe any significant difference (Fig 2A). The same was true for SREBF1c mRNA (Fig 
2A).  
In addition to transcriptional regulation (45, 46), SREBF1 can be activated by cleavage from 
its precursor to its mature form upon insulin treatment (38). Because p62 has been 
demonstrated to upregulate IGF2 in both mouse (24) as well as in human livers (27), we 
hypothesized that p62 regulates SREBF1 on protein level. We observed significantly 
increased levels of the mature isoform of SREBF1 after overexpression of p62 in HepG2 (Fig 
2B). The SREBF1 mature form in p62 transgenic mice behaved similarly, but quantified 
values were not statistically significant (Fig 2C). The precursor showed neither an induction 
in p62 overexpressing HepG2 (Fig 2B) nor in p62 transgenic mice (Fig 2C). Knockdown of 
p62 by siRNA resulted in reduced levels of both the SREBF1 precursor as well as the mature 
form of SREBF1 (Fig 2B). 
Suggesting IGF2 to be responsible for SREBF1 activation, we treated HepG2 cells with IGF2, 
and indeed observed higher amounts of mature SREBF1 in their nuclei (Fig 2D). 
Antagonization of IGF2 activity with an IGF2 specific antibody in HepG2 reduced the levels 
of ELOVL6 and the nuclear form of SREBF1 compared to their respective controls (Fig 2E). 
In human liver tissue, in which p62 and ELOVL6 correlated, we also observed a distinct 
correlation of IGF2 and ELOVL6 expression levels (Fig 2F). In the same tissues (n = 35) we 
could confirm a correlation between p62 and IGF2 (r = 0.41, p = 0.02) as recently reported for 
a cohort of HCC patients (27). 
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Figure 2. Implications of p62 on lipogenic pathways.  
Real-time RT-PCR (n=3-6, triplicate, A) or Western blot (n=3, duplicate, B) of HepG2 
transfected with either p62 siRNA (si p62) or p62 overexpression vector (p62) and their 
respective controls (si co, co-v).  
A. MLXIPL, NR1H3, and SREBF1c mRNA.  
B. Precursor (SREBF1 pre) and mature SREBF1 (SREBF1 ma).  
C. SREBF1 pre and SREBF1 ma Western blot of wild-type (wt) and p62 transgenic (p62 tg) 
livers (n=6). 
D. SREBF1 pre and SREBF1 ma Western blot on cytosolic and nuclear proteins of HepG2 
treated with IGF2 (n=9, duplicate).  
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E. SREBF1 pre and SREBF1 ma and ELOVL6 Western blot on cytosolic and nuclear 
proteins of HepG2 (co) incubated with neutralizing IGF2 antibody (IGF2 AB, 48 h) (n=4, 
duplicate).  
F. Real-time RT-PCR for ELOVL6 and p62 of 35 liver tissues normalized on ACTB mRNA 
levels.  
 
The fatty acid synthase (FASN) as an important lipogenic enzyme displays also a target of 
SREBF1 activation, which is why we hypothesized that p62-induced lipid accumulation 
might be mediated via FASN induction. Interestingly, however, FASN mRNA and protein 
levels were not changed upon p62 overexpression and increased upon p62 knockdown (Fig 
3A, B). Concordantly, the p62 transgenics revealed reduced levels of FASN protein (Fig 3C). 
The analysis of human liver samples showed no correlation between p62 and FASN mRNA (r 
= -0.1, p = 0.58). To reassess the unforeseen behaviour of the direct SREBF1 target FASN, 
we had a closer look on stearoyl-CoA desaturase (delta-9-desaturase) (SCD1, SCD) and 
acetyl-CoA carboxylase alpha (ACC, ACACA) mRNA, which are SREBF1 targets and 
important enzymes in lipogenesis. Interestingly, neither p62 knockdown nor p62 
overexpression revealed changes in SCD or ACACA mRNA levels (Fig 3D). Since most 
lipogenic genes are coordinately regulated by SREBF1 and MLXIPL (47), we speculated that 
inversely regulated MLXIPL action might reverse the action of activated SREBF1. Therefore, 
we had a closer look on pyruvate kinase, liver and RBC (L-PK, PKLR) expression, which is 
exclusively regulated by MLXIPL (48). Indeed, p62 regulation of PKLR mRNA exhibited the 
same expression pattern compared to MLXIPL mRNA: PKLR mRNA was increased after p62 
knockdown and decreased after p62 overexpression (Fig 3E).  
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Figure 3. Effect of p62 on lipogenic genes. 
A. FASN real-time RT-PCR of HepG2 transfected with either p62 siRNA (si p62, n=3, 
triplicate) or p62 overexpression vector (p62, n=5, triplicate) and their respective controls (si 
co, co-v). 
B. FASN Western blot of HepG2 transfected with si p62 or p62 (n=3, duplicate). 
C. Representative FASN Western blot of wild-type (wt) and p62 transgenic (p62 tg) livers 
(n=5, each).  
D. SCD and ACACA real-time RT-PCR of HepG2 transfected with either p62 siRNA (n=3, 
triplicate) or p62 overexpression vector (n=5, triplicate) and their respective controls. 
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E. PKLR real-time RT-PCR of HepG2 transfected with either p62 siRNA (n=4, triplicate) or 
p62 overexpression vector (n=5, triplicate) and their respective controls. 
 
Regulation of lipolytic pathways 
Our data as yet suggested a distinct action of p62 on fatty acid composition (i.e. chain length), 
but rather no effect on lipogenic enzymes. We therefore suggested that the elevated levels of 
lipids in p62 livers might rather be facilitated by a decreased β-oxidation. We therefore tested 
PPARA expression upon both p62 knockdown and overexpression in human hepatoma cells, 
and in p62 transgenic mice. The data revealed a downregulation of PPARA mRNA after p62 
overexpression in cells (Fig 4A) and a lack of effect in the p62 transgenic mouse model (Fig 
4B). Therefore, the investigation of PPARA expression does not provide conclusive data on a 
potentially decreased β-oxidation due to p62. 
Mitochondrial β-oxidation is regulated by carnitine palmitoyltransferase 1A (CPT1A) activity 
(Fig 4C), which is controlled by malonyl-CoA. Malonyl-CoA levels depend on the palmitoyl-
CoA-mediated inhibition of acetyl-CoA carboxylase alpha (ACACA). Malonyl-CoA levels 
were below the detection limit of UHPLC-MS/MS analysis. Still, reduced palmitoyl-CoA 
levels (37 ± 12%) as found in p62 transgenic animals suggested that attenuated mitochondrial 
β-oxidation is responsible for ELOVL6-induced steatosis. 
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Figure 4. Implications of p62 on lipolytic pathways and summary. 
A. PPARA real-time RT-PCR of HepG2 transfected with either p62 siRNA (si p62, n=3, 
triplicate) or p62 overexpression vector (p62, n=5, triplicate) and their respective controls (si 
co, co-v). 
B. PPARA real-time RT-PCR of wild-type (wt) and p62 transgenic (p62 tg) livers (n=5, each). 
C. p62 overexpression decreases FASN expression by MLXIPL depletion and induces IGF2 
expression. Reduced FASN levels lead to malonyl-CoA accumulation. IGF2 promotes the 
maturation of SREBF1, which increases ELOVL6 expression, leading to an increased C18 to 
C16 ratio. The reduced inhibition of palmitoyl-CoA on ACACA activity elevates malonyl-
CoA levels, which inhibit the CPT1A-activity and therefore mitochondrial β-oxidation.  
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2.2.7 Discussion 
The p62-induced steatosis is characterized by an increase in almost all lipid classes with the 
most distinct effect on triglycerides (26). Accordingly, we here observe an elevated 
abundance of almost all fatty acids (Table 1). Due to unchanged serum cholesterol and 
triglyceride levels in p62 transgenics compared to wild-type animals (24) it is unlikely that 
hepatic lipid accumulation is due to reduced lipid export from the liver or increased lipid 
uptake.  
Excess hepatic lipid incorporation is often associated with inflammatory events, which link a 
simple steatosis to NASH (6). We here show that p62 transgenic mice also display 
inflammatory signs, as validated by increased F4/80 and leukocyte infiltrates. The 
inflammation is rather mild, though, and does not result in elevated transaminase levels (24), 
which might also be linked to cytoprotective actions of p62 (27). Despite lipid accumulation 
and an inflammatory environment, development of insulin resistance is absent in p62 
transgenic mice confirming our previous data (24), which suggest slightly elevated glucose 
tolerance.  
In addition to the general increase in lipids in p62 transgenic livers we could observe an 
increased ratio of C18 to C16 fatty acids. Accordingly, ELOVL6, which catalyzes the 
elongation of C16 to C18 fatty acids (17), is increased in p62 transgenic mice. Our results 
from HepG2 cells and human liver tissues are in line with these findings. Recently, 
Matsuzaka et al. reported that overexpression of ELOVL6 promotes NASH in mice and 
humans (20). What is more, ELOVL6 expression specifically characterizes steatotic events 
being linked to inflammation (21, 22). This is in line with the finding that p62 transgenic 
mice, which both exhibit increased levels of ELOVL6 and show signs of liver inflammation. 
Pathways being responsible for the upregulation of this pathophysiological regulator of liver 
disease have as yet been unknown. SREBF1 is an important transcription factor that regulates 
lipid metabolism and contributes to the pathophysiology of the metabolic syndrome (49, 50). 
Our data demonstrate a p62-dependent cleavage of SREBF1 into its active form. SREBF1 
gene expression as well as its cleavage-induced activation is enhanced by insulin, leading to 
its binding to sterol-response element, which is located in the promoters of its target genes 
(51). HepG2 cells, in which the transcriptional regulator of SREBF1 NR1H3 was activated, 
displayed increased SREBF1c mRNA levels (52-54), whereas SREBF1a expression, the 
dominant isoform in cultured hepatocytes (55), was not regulated by NR1H3 activation (54, 
56, 57). Since neither p62 knockdown nor p62 overexpression showed any effect on NR1H3 
expression, it is hardly surprising that SREBF1c mRNA levels were not affected by p62. 
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IGF1 and insulin treatment have been shown to induce SREBF1 in sebocytes via activation of 
the insulin- and IGF1-receptor (58). IGF2 binds to insulin receptor, IGF1-receptor, and IGF2-
receptor, with moderate to high affinity (45). Human hepatoma cell lines overexpressing p62 
and p62 transgenic animals have been shown to express high levels of IGF2 mRNA (24, 27). 
We here report a p62-mediated induction of SREBF1 and ELOVL6, which depends on IGF2 
expression. This causal link is supported by the correlation of p62, IGF2, and ELOVL6 
expression in human liver tissue. 
Our data revealed an upregulation of MLXIPL by p62 knockdown, while SREBF1 is 
inactivated. Vice versa, a MLXIPL downregulation occurs after p62 overexpression, while 
SREBF1 is activated. In fact, the literature reports that SREBF1 overexpression reduces 
MLXIPL expression (41). Since MLXIPL knockout animals show improved plasma glucose 
control (48, 59), the improved glucose tolerance exhibited in p62 transgenic animals (24) can 
be explained by MLXIPL downregulation and increased Igf2 levels.  
Although SREBF1 can induce FASN (41), we observed that p62 decreased FASN levels, 
while SREBF1 was activated. The effects of p62-induced SREBF1 activation seems to be 
abrogated by the parallel decreased MLXIPL expression, which is in line with the finding that 
50% of lipogenic gene expression is associated to MLXIPL (9). Interestingly, the p62 model 
is characterized by a higher sensitivity of ELOVL6 towards SREBF1 activation than to 
MLXIPL depletion. FASN, on the other hand, is stronger affected by attenuated MLXIPL 
levels. In this context, Yu et al. recently reported that human fibroblasts, in which MLXIPL 
was knocked down by a lentiviral short hairpin RNA plasmid showed strongly decreased 
levels of FASN mRNA expression, but rather no effect on ELOVL6 expression (60) 
suggesting that MLXIPL shows stronger transcriptional activation towards FASN than to 
ELOVL6. PKLR, which is uniquely induced by MLXIPL (61), is reversely regulated by p62 
and is therefore convergent to the MLXIPL expression. 
Despite the effect of p62 on FASN in HepG2 and in the murine mouse model, we could not 
detect any correlation between p62 and FASN expression in human liver samples. Also 
published data showed no elevation of FASN in human NAFLD (62). Concordantly, 
Donnelly et al. reported that de novo lipogenesis only to a minor extent contributes to elevated 
hepatic lipids as found in human NAFLD (63). 
In line with these findings, the literature describes that liver-specific knockout of FASN did 
not rescue the animals from the development of a fatty liver (64) and Jones et al. recently 
reported the development of steatosis in TSC22D4 overexpressing mice despite decreased 
FASN mRNA levels (65). Most interestingly, also animals overexpressing ELOVL6 show 
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increased liver triglycerides and at the same time reduced FASN expression (20). Therefore, 
fatty acid synthesis appears not to be the pivotal step in p62-mediated steatosis development.  
One of the important inducers of peroxisomal and mitochondrial β-oxidation pathways in the 
liver is PPARA (10). PPARA agonists like fenofibrate reduce steatosis in mice with a 
hereditary fatty liver (66). PPARA is downregulated in p62 overexpressing HepG2, but not in 
the p62 transgenics, suggesting that p62 does not facilitates lipolysis via PPARA. We suggest 
that p62 induces high fatty acid levels due to elevated malonyl-CoA levels. Indeed, the 
mitochondrial β-oxidation pathway as the central lipolytic pathway is negatively regulated by 
high malonyl-CoA levels (67). ELOVL6 can elevate malonyl-CoA since it reduces the levels 
of its substrate palmitoyl-CoA in p62 transgenic mice (Fig 4C). Since fatty acids in p62 
transgenic mice are mostly bound in triglycerides (26) and only free fatty acids are converted 
to acyl-CoAs (68), triglyceride-bound palmitic acid can not be converted into palmitoyl-CoA. 
Whereas high levels of palmitoyl-CoA inhibit the activity of the enzyme responsible for 
malonyl-CoA synthesis (69), i.e. acetyl-CoA carboxylase alpha (ACACA) (67), low levels 
promote the generation of malonyl-CoA via ACACA. Consequently, the mitochondrial β-
oxidation is reduced due to malonyl-CoA-mediated attenuation in CPT1A activity (70) (Fig 
4C). Pharmacological inhibition of CPT1A is associated with the development of steatosis 
and steatohepatitis (71, 72). Furthermore, a tamoxifen-induced steatosis in rats, which 
strongly inhibited FASN expression, was characterised by an accumulation of malonyl-CoA 
and therefore decreased CPT1A activity (73) (Fig 4C).  
In summary, our data provide evidence of p62 as an inducer of ELOVL6, a 
pathophysiological promoter of NASH. ELOVL6 overexpression results in a subsequent 
production of a deleterious fatty acid profile, which finally induces hepatic steatosis (Fig 4C). 
This study underlines the detrimental role of p62 in liver disease. 
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2.2.10 Supplement 
Supplemental data Figures 
 
 
Supplemental data Figure I: Representative Palmitoyl-CoA dilution series 
 
 
Supplemental data Figure II: Representative palmitoyl-CoA measurement in mouse livers 
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Supplemental data Table 
Nr. diagnosis 
1 cirrhosis, hepatitis 
2 cirrhosis, hepatitis 
3 liver cirrhosis, primary biliary cirrhosis 
4 cirrhosis 
5 cirrhosis, hepatitis 
6 cirrhosis, hepatitis 
7 liver cirrhosis, hepatitis C virus 
8 liver cirrhosis, hepatitis C virus 
9 liver cirrhosis, hepatitis B virus 
10 liver cirrhosis, alcoholic liver 
11 liver cirrhosis, hepatitis B virus 
12 cirrhosis, viral hepatitis 
13 liver cirrhosis, alcoholic hepatitis 
14 liver cirrhosis, hepatitis C virus 
15 liver cirrhosis, Budd-chiary-S. 
16 liver cirrhosis, hepatitis C virus 
17 liver fibrosis, liver cirrhosis 
18 liver cirrhosis, liver cirrhosis alcoholic 
19 liver cirrhosis 
20 liver cirrhosis, viral hepatitis 
21 liver cirrhosis, hepatitis C virus 
22 liver cirrhosis 
23 liver cirrhosis, hepatitis B virus 
24 liver cirrhosis 
25 cirrhosis, hepatitis C virus 
26 liver cirrhosis, hepatitis B virus 
27 liver cirrhosis, cryptogen., viral hepatitis 
28 liver cirrhosis, viral hepatitis 
29 liver cirrhosis, viral hepatitis 
30 liver cirrhosis 
31 liver cirrhosis, alcoholic liver cirrhosis 
32 liver cirrhosis 
33 liver cirrhosis, hepatitis B virus, hepatitis C virus 
34 liver cirrhosis, hemachromatome 
35 liver cirrhosis, alpha-1 antitrypsin deficiency 
Supplemental data Table I: Patients / Diagnosis 
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p62 has been shown to promote NAFLD (Laggai et al., 2014; Simon et al., 2014a), and to 
modify pathways involved in cancerogenesis (Tybl et al., 2011). In this study, the p62-
mediated overexpression of the growth factor IGF2 should also be validated for the human 
system. Therefore, we investigated the abundance and implications of p62 and IGF2 in 
human HCC and in human cell lines. Furthermore, the effect of p62 and IGF2 on 
antiapoptotic pathways and especially the activation of the protein kinase B 
(PKB)/AKT/PI3K pathway should be validated. 
 
IGF2 mRNA binding protein p62/IMP2-2 in hepatocellular carcinoma: antiapoptotic 
action is independent of IGF2/PI3K signaling. 
Sonja M. Kessler, Juliane Pokorny, Vincent Zimmer, Stephan Laggai, Frank Lammert, 
Rainer M. Bohle, and Alexandra K. Kiemer. 
 
This research was originally published in American Journal of Physiology - Gastrointestinal 
and Liver Physiology. Kessler, S.M., Pokorny, J., Zimmer, V., Laggai, S., Lammert, F., 
Bohle, R.M., and Kiemer, A.K. IGF2 mRNA binding protein p62/IMP2-2 in hepatocellular 
carcinoma: antiapoptotic action is independent of IGF2/PI3K signaling. AJP-Gastrointest Liver 
Physiol. 2013; 304: G328–G336. doi:10.1152/ajpgi.00005.2012. Copyright © 2013, the 
American Physiological Society. 
 
The full text article can also be found at: 
http://ajpgi.physiology.org/content/304/4/G328 
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2.3.2 Title page 
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2.3.3 Abstract 
Background and aims: The insulin-like growth factor II (IGF2) mRNA binding protein (IMP) 
p62/IMP2-2, originally isolated from an HCC patient, induces a steatotic phenotype when 
overexpressed in mouse livers. Still, p62 transgenic livers do not show liver cell damage but 
exhibit a pronounced induction of Igf2 and activation of the downstream survival kinase Akt. 
Aim of this study was to investigate the relation between p62 and IGF2 expression in the 
human system and to study potential antiapoptotic actions of p62. 
Methods: p62 and IGF2 mRNA levels in human paraffin-embedded tissue were assessed by 
real-time RT-PCR. For knockdown and overexpression experiments human hepatoma HepG2 
and PLC/PRF/5 cells were transfected with siRNA or plasmid DNA. Phosphorylated AKT 
and ERK1/2 were analysed by Western blot.  
Results: Investigations of 32 human HCC tissues showed a strong correlation between p62 
and IGF2 expression. Of note, p62 expression was increased markedly in patients with poor 
outcome. In hepatoma cells overexpression of p62 lowered levels of doxorubicin-induced 
caspase-3-like activity. Vice versa, knockdown of p62 resulted in increased doxorubicin-
induced apoptosis. However, neither PI3-K inhibitors nor a neutralizing IGF2 antibody 
showed any effects. Western blot analysis revealed increased levels of phosphorylated 
ERK1/2 in hepatoma cells overexpressing p62 and decreased levels in p62 knockdown 
experiments. When p62 overexpressing cells were treated with ERK1/2 inhibitors, the 
apoptosis-protecting effect of p62 was completely abrogated.  
Conclusions: Our data demonstrate that p62 exerts IGF2-independent antiapoptotic action, 
which is facilitated via phosphorylation of ERK1/2. Furthermore, p62 might serve as a new 
prognostic marker in HCC. 
Keywords: IMP, hepatocellular carcinoma, apoptosis, ERK, chemoresistance
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2.3.4 Introduction 
The incidence of hepatocellular carcinoma (HCC) is rising in most industrialized countries 
not least due to metabolic risk factors such as obesity and diabetes mellitus and the increasing 
prevalence of non-alcoholic fatty liver disease (NAFLD (12, 48). p62/IMP2-2 is a member of 
the family of insulin-like growth factor II (IGF2)-mRNA binding proteins and represents a 
splice variant of IMP2, where exon 10 of the IMP2 gene is skipped (11). p62 was originally 
identified as an autoantigen in a patient with HCC (57) and was shown to be expressed in 1/3 
to 2/3 of HCC (33, 56). Interestingly, p62 is also expressed in α-fetoprotein negative HCC 
(33). The family member IMP3 has been shown to be implicated in growth promotion, 
carcinogenesis, angiogenesis, and tumor progression in different tumor types (6, 20, 22, 25). 
A pathophysiologic role for p62 in malignant diseases, however, is as yet widely unknown. 
p62 transgenic mice expressing the transgene exclusively in the liver develop a fatty liver 
phenotype (51) suggesting a critical role for p62 in liver metabolism. Still, p62 transgenic 
livers do not show liver cell damage but exhibit a pronounced induction of the growth factor 
Igf2 and activation of the downstream survival kinase phosphoinositide 3 (PI3)-kinase/Akt 
pathway. IGF2 plays a key role in mammalian growth through metabolic and growth-
promoting effects and exerts antiapoptotic action (36, 37). The interaction of p62 and IGF2 
might be of special interest with regard to the tumor promoting nature of IGF2. In fact, 
overexpression of IGF2 and pronounced activation of AKT has been described in HCC (5, 8, 
34, 49). Quite in contrast, reduced IGF2 expression was shown to enhance survival from HCC 
(54).  
Since a potential interaction of p62 and IGF2 is unknown in human HCC, we investigated 
their relationship and functional aspects regarding cell survival and proliferation. We 
observed that p62 expression correlates with both IGF2 expression and poor outcome in 
human hepatocellular carcinoma. p62 exerted antiapoptotic action in human hepatoma cells 
independent of PI3-K signaling, but rather facilitated via extracellular regulated kinases 
(ERK) 1/2.  
 
2.3.5 Materials and Methods 
Animals 
All animal procedures and protocols were approved by an independent review committee 
(AZ: 391 2.2.2) Mice were kept under controlled conditions in terms of temperature, 
humidity, 12 h day/night rhythm and food delivery. p62 transgenic mice were established as 
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previously described (51). In short, mice carrying a liver enriched activator protein promoter 
under the control of a tetracycline transactivator were crossed with p62 transgenic mice, in 
which the human p62 is under the control of the transrepressive responsive element 
cytomegaly virus (TRE-CMVmin). The double positive offspring expresses p62 exclusively 
in the liver. 
 
Real-time quantitative polymerase chain reaction  
Experiments and quantification were performed as described in detail previously (2). RNA 
from human HCC samples was isolated using the QiaAmp RNA-FFPE-Kit according to 
manufacturers’ instructions. Sequences and conditions are given in table 1.  
 
Isolation of primary murine hepatocytes 
Hepatocytes were isolated according to a modified version of the two-step collagenase 
perfusion method of Seglen (13, 44) with a viability exceeding 80%. Cells were cultured on 
collagen-coated plates for one day before treatment.  
 
MTT Assay 
Cells were cultured on 96-well tissue culture plates and every 24 h an MTT assay was 
performed for up to 4 days. Cells were then incubated with MTT (0.5 mg/ml) solution for 2 h, 
MTT solution was aspirated, cells were lysed and measured at 550 nm and at 690 nm as 
control wavelength.  
 
Caspase-3-like activity assay 
In primary murine hepatocytes apoptosis was induced by addition of 0.4 µg/ml actinomycin D 
(Act D) for 15 min and 100 ng/ml TNF-α for 20 h. HepG2 cells were treated with 12.5 µg/ml, 
PLC/PRF/5 with 50.0 µg/ml doxorubicin for 20 h. Cells were then washed twice, lysed and 
centrifuged. The substrate solution containing benzyloxycarbonyl-Asp-Glu-Val-Asp-
aminofluoromethylcoumarin was added to the supernatant, and generation of free fluorescent 
7-amino-4-trifluoromethyl coumarin was determined according to Kulhanek-Heinze et al. 
(28).  
 
Western blot analysis 
Western blots were performed as previously described (51). Antibodies used were specific to 
phospho-AKT (Ser473), phospho-ERK1/2, total ERK1/2, phospho-Insulin Receptor, total 
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Insulin Receptor (New England Biolabs, Frankfurt a. M., Germany), and α-tubulin (Sigma, 
Thermo Fisher Scientific, Karlsruhe, Germany). 
 
Cell transfection 
For overexpression assays, pcDNA3.1/CT-GFP-TOPO® p62 sense or the antisense construct 
was introduced into HepG2 or PLC/PRF/5 cells using jetPEITM-Hepatocyte transfection 
reagent (Polyplus-transfection, New York, USA). Knockdown was performed with 
sip62/IMP2 and control siRNA using INTERFERinTM (Polyplus-transfection, New York, 
USA) transfection reagent as recommended under reverse transfection in the manufacturer’s 
guidelines. Inhibition of the IGF2/PI3-K pathway was done using the PI3-K-inhibitors 
LY294002 (10 µM) and wortmannin (800 mM) as well as an IGF2 antibody (ab9574, Abcam, 
United Kingdom). PD98059 and U126 (both 10 µM) served as ERK1/2-inhibitors (17). 
Inhibition was achieved by pretreatment for 1 h with inhibitors and for 2 h with the IGF2 
antibody. Neutralizing effect of IGF2 antibody was verified by Western Blot analysis after 
treatment with recombinant human IGF2 (R&D Sytems, Wiesbaden, Germany). 
 
Immunohistochemistry 
Staining of the paraffin-embedded sections was performed with the CSA II Kit (Dako, 
Hamburg, Germany). Primary antibodies used were specific to phosphoERK1/2 (New 
England Biolabs, Frankfurt a. M., Germany) and p62 (33, 51). 
 
Human HCC tissues 
Paraffin-embedded liver samples from randomly selected pseudonymised HCC patients who 
underwent liver resection at the Saarland University Medical Center between 2005 and 2010 
were obtained. The study protocol was approved by the local Ethics Committee (Kenn-Nr. 
47/07). Table 2 summarizes the clinical data. TNM staging was performed according to the 
NCCN Hepatobiliary Cancers Clinical Practice Guidelines in Oncology (NCCN Guidelines™ 
for Hepatobiliary Cancers V2.2012 © 2011 National Comprehensive Cancer Network, Inc. 
cited with permission from the NCCN). T classification was ascertained on the resected 
specimen, whereas N and M classifications were determined by clinical radiological staging 
for most of the patients. 
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Statistical analysis 
Data analysis and statistics were performed using Origin software (OriginPro 8.1G; 
OriginLabs). All data are displayed as mean values ± SEM. Statistical differences were 
estimated by independent two-sample t-test. Human FFPE HCC samples were tested by 
Wilcoxon rank-sum test. Kaplan-Meier-Survival analysis was tested by log rank test. All are 
two-sided and differences were considered statistically significant when p values were less 
than 0.05. 
 
2.3.6 Results 
p62 and IGF2 expression in human HCC samples  
The analysis of 32 human HCC tissues showed increased levels of p62 and IGF2 in tumor 
tissue as compared to matched normal tissue (Fig. 1A). Furthermore, a significant correlation 
between p62 and IGF2 expression was observed (Fig. 1B). Kaplan-Meier survival analysis of 
patients with high p62 expression (upper quartile) versus low p62 expression (lower quartile) 
was not significant, but revealed a trend to shorter survival in patients with high p62 
expression in liver tissue (Fig. 1C). Therefore, p62 expression was tested for different 
parameters of poor outcome of the corresponding patient. p62 expression was significantly 
higher in tumors with increased tumor size and in grade 2 and 3 tumors versus grade 1 tumors 
(Fig. 1D). p62 expression correlated with tumor stage using both BCLC and TNM staging 
system (Fig. 1E, F). Altogether, the subgroup with high p62 expression showed poorer 
outcome characterized by intermediate to advanced Barcelona staging (stages B or C), TNM 
staging III or IV, multinodularity, and increased tumor diameter (Fig. 1G). 
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Fig. 1. p62 and IGF2 expression in human HCC samples (A) p62 and IGF2 mRNA 
expression in human HCC samples (n=32) compared to matched normal tissue. (B) 
Correlation of p62 mRNA and IGF2 mRNA in human HCC samples. (C) Kaplan-Meier 
survival analysis of the upper quartile (high p62) vs. the lower quartile (low p62) of p62 
mRNA expression in HCC samples. (D) p62 mRNA expression in HCC samples ordered by 
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different clinicopathological parameters of poor prognosis of the corresponding patient: 
Barcelona Clinic Liver Cancer (BCLC), TNM classification and staging, grading, uni- or 
multinodularity, tumor size and recurrence. (E, F) Correlation data of p62 expression to tumor 
stage for BCLC (E) and TNM (F) staging system. (G) Comparison of p62 mRNA expression 
with prognostic clinical data from HCC patients, such as BCLC, TNM staging, 
multinodularity, and tumor size.  
 
Relationship between p62 and IGF2 expression in human hepatoma cells 
In order to determine whether the presence of p62 induces IGF2 expression in the human 
system as previously observed in p62 transgenic mice (51), p62 was knocked down by siRNA 
in HepG2 cells. Knockdown of p62 decreased IGF2 expression (Fig. 2A). Vice versa, 
overexpression of p62 resulted in increased IGF2 mRNA levels (Fig. 2B). Because of the 
proliferating and antiapoptotic features of IGF2 we investigated the effect of p62 on 
proliferation and apoptosis. After knockdown of p62, however, no effect on cell proliferation 
was observed (Fig. 2C).  
Basal levels of apoptosis were not altered in livers of transgenic animals (data not shown). 
TNF-α/Act D-induced caspase-3-like activity in primary murine hepatocytes from p62 
overexpressing mice, however, was attenuated compared to control cells (Fig. 2D). In the 
human system overexpression of p62 in HepG2 cells decreased doxorubicin-induced 
apoptosis (Fig. 2E). Vice versa, knockdown of p62 in HepG2 cells resulted in increased 
doxorubicin-induced caspase-3-like activity (Fig. 2F). 
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Fig. 2. Proliferation and apoptosis (A) p62 and IGF2 mRNA expression 48 h after siRNA 
knockdown of p62 (si p62) in HepG2 cells compared to random siRNA control (si co). (B) 
p62 and IGF2 mRNA expression 48 h after p62 overexpression (p62) in HepG2 normalized to 
control vector carrying the antisense plasmid (co-v). (C) Proliferation of HepG2 cells after 
knockdown of p62 (si p62) compared to random siRNA (si co). (D) Caspase-3-like activity 
levels of primary murine hepatocytes of p62 transgenic animals (p62) and wild-type animals 
(wt) induced by TNF-α/Act D treatment. Data is expressed as fold induction of apoptosis 
compared to untreated control. (E, F) Doxorubicin-induced caspase-3-like activity in HepG2 
after transfection either with random siRNA (si co) or p62 siRNA (si p62) (E) or with p62 
antisense construct (co-v) or p62 sense construct (p62) (F). 
 
Antiapoptotic effect of p62 is independent of PI3-K signaling  
Since p62 transgenic animals showed increased levels of phophorylated Akt (51), we 
speculated that the IGF2/PI3-K pathway is involved in the antiapoptotic effect of p62. In 
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order to determine the involvement of IGF2 in the antiapoptotic effect, p62 was 
overexpressed in HepG2 cells followed by inhibition of the IGF2/PI3-K pathway. Neither the 
PI3K-inhibitors LY294002 and wortmannin nor a neutralizing IGF2 antibody lowered the 
antiapoptotic effect of p62 (Fig. 3A). The neutralizing capacity of the IGF2 antibody was 
confirmed by Western blot analysis of phosphorylated insulin receptor (Fig. 3B). The 
independence of p62 expression and PI3K/AKT signaling in the human system was 
confirmed by p62 knockdown or overexpression, and neither approach affected 
phosphorylation of AKT significantly (Fig. 3C, D).  
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Fig. 3. PI3-K signaling (A) Inhibition of doxorubicin-induced apoptosis by p62 determined 
by caspase-3-like activity. Inhibition was achieved by using either a neutralizing IGF2 
antibody (Ab) or the PI3-K inhibitors Ly294002 (Ly) and wortmannin (Wo). Data are 
expressed as percent inhibition of doxorubicin-induced apoptosis in p62 transfected cells (co). 
(B) Neutralizing effect of IGF2 antibody verified by Western Blot analysis of phosphorylated 
(pIR) and total (tIR) insulin receptor levels in HepG2 after treatment with 75 ng/ml 
recombinant human IGF2 with and without treatment with IGF2 antibody (C, D). 
Phosphorylated AKT levels after knockdown (si co: random siRNA, si p62: p62 siRNA) (C) 
and overexpression of p62 (co-v: antisense construct, p62: sense construct) (D). (E, F): 
densitrometric analysis of Western Blots from C and D. 
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p62 protects from apoptosis via phosphorylation of ERK1/2 
Another survival pathway that is often altered in cancer is the mitogen activated protein 
kinase (MAPK) pathway (29). When p62 overexpressing HepG2 cells were treated with ERK 
1/2 inhibitors, the apoptosis-protecting effect of p62 was completely abrogated (Fig. 4A). 
Knockdown of p62 in HepG2 cells resulted in significantly decreased phophorylation of 
ERK1/2 (Fig. 4B, D). Vice versa, overexpression of p62 activated ERK1/2 markedly (Fig. 4C, 
D). In order to check the relevance of these findings in another hepatoma cell line, we 
investigated PLC/PRF/5 cells. p62 regulated IGF2 expression also in this cell line: p62 
knockdown downregulated IGF2 mRNA by 40.88% (p=0.023) and p62 overexpression 
induced IGF2 mRNA 2.01-fold (p=0.016). Still, the IGF2 antibody did not affect 
chemosensitivity, whereas both ERK inhibitors significantly abrogated apoptosis induction 
(Fig. 4D). As seen in HepG2 cells, p62 induced ERK activation, as proven by knockdown and 
overexpression strategies also in PLC/PRF/5 (Fig. 4E-H). Finally, in tissue samples from 
HCC patients activation of ERK was observed in hepatocytes, which showed high p62 
expression (Fig. 4I). 
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Fig. 4. ERK signaling (A, E) Inhibition of doxorubicin-induced apoptosis by p62 determined 
by caspase-3-like activity in HepG2 (A) and PLC/PRF/5 (E) cells. Inhibition was achieved by 
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using either a neutralizing IGF2 antibody (Ab) or the ERK inhibitors PD98059 (PD) and 
U126 (U). Data are expressed as percent inhibition of doxorubicin-induced apoptosis in p62 
transfected cells (co). (B-D) and (F-H): phosphorylated ERK levels after knockdown of p62 
in HepG2 (B) and PLC/PRF/5 (F) cells (si co: random siRNA, si p62: p62 siRNA) and 
overexpression of p62 in HepG2 (C) and PLC/PRF/5 (G) cells (co-v: antisense construct, 
p62: sense construct). Densitrometric analysis of Western blots from HepG2 (D) or 
PLC/PRF/5 (H) cells upon knockdown or overexpression of p62. Data are expressed as ratio 
of phosphorylated ERK to total ERK signal intensities with values for respective controls (si 
co or co-v) set as 100%. (I) Microphotography displaying a representative hepatocellular 
carcinoma case (a: HE staining, b: total ERK1/2 immunostaining) with positive specific 
pERK1/2 immunostaining (c) and corresponding positive p62 immunostaining (d) in tumor 
tissue. Original magnification: 100x. 
 
2.3.7 Discussion 
The IGF2 mRNA binding protein p62 was originally identified as a tumor-associated 
autoantigen with autoantibodies against p62 detected in 21% of HCC patients (55) and in 
several other types of cancer (40, 58). p62 protein was reported to be expressed in HCC 
tissue, but not in healthy surrounding tissue in 30% (33, 56) and up to 61.5% of HCCs (47). 
Concordantly, our data show significantly increased levels of p62 mRNA in HCC tissue.  
The IMP family member IMP3 was suggested as a prognostic marker for tumor malignancy 
and prognosis in different cancers, such as pancreatic ductal adenocarcinoma, neuroblastoma, 
prostate cancer, and colon cancer (7, 22, 24, 47). Similarly, IMP1 was observed to correlate 
with metastasis and shorter survival in colon cancer (14) and ovarian carcinoma (27). In line 
with these findings we observed a correlation between p62 expression and poor prognostic 
markers. Higher p62 expression was observed in tissues from intermediate or advanced 
tumors showing multinodularity, increased tumor size, poorer differentiation, and early 
recurrence of tumors, all of which indicate a more severe status of disease. Since p62 mRNA 
levels were increased in G2/G3 vs. G1 patients one might speculate that p62 expression might 
serve as a valuable tumor marker in the future. However, higher numbers of patients need to 
be analyzed. 
Our HCC cases comprised different etiologies, hence the limited sample number did not allow 
to correlate etiologies with the extent of p62 expression. Neither an association between viral 
infection (21) nor a potential correlation with steatohepatitis caused by NAFLD could be 
found for p62, although p62 overexpression in mouse livers induced a prominent steatotic 
phenotype (51).  
The p62 transgenic mouse model showed a pronounced expression of the metabolic and 
antiapoptotic growth factor Igf2 (51). We now demonstrate that p62 expression correlates 
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with IGF2 expression also in human HCC. In fact, a causal effect of p62 on IGF2 expression 
is proven by both knockdown and overexpression of p62 in two different hepatoma cell lines. 
IGF2 is a well described antiapoptotic factor overexpressed in HCC (5, 32, 41, 42, 50) and 
other tumor tissues (3, 9, 45). The balance between apoptosis and survival is often disrupted 
due to antiapoptotic signals occurring in cancer (16). Accordingly, hepatocarcinogenesis and 
promotion of HCC is characterized by defective apoptosis and increased cell proliferation (18, 
38). Proliferation did not seem to be influenced by p62 expression, which has also been 
shown for IMP3 in a hepatoma cell line (25). Interestingly, however, both knockdown and 
overexpression of p62 in hepatoma cells verified an antiapoptotic effect of p62. The IMP 
famlily members IMP1 and IMP3 have recently been demonstrated to promote cell survival 
and cancer cell proliferation (26, 31), whereby IGF2 seems to mediate apoptosis protection 
(31). 
HCC is characterized by alterations in several important cellular signaling networks including 
the PI3-K and the ERK pathways (52). Constitutive activation of the PI3-K/AKT pathway has 
been firmly established as a major determinant of tumor cell growth and survival in several 
tumors (8). In HepG2 cells IGF1 has been demonstrated to have the ability to reverse 
apoptotic signaling by activation of the PI3-K/AKT signaling (1). IGF1 binds to the IGF1 
receptor whose autophosphorylation is followed by phosphorylation of intracellular targets 
and finally leads to activation of the PI3-K and the ERK pathways (39). IGF2 was also 
demonstrated to act via the PI3-K/AKT pathway (30). Unexpectedly, the altered IGF2 
expression after knockdown or overexpression of p62 did not result in changes in AKT 
activation in HepG2 cells. Another recent study also showed independence of high IGF2 
mRNA expression and phophorylation of AKT in human HCC tissues (50). Interestingly, p62 
transgenic animals only exhibited increased Akt phophorylation in five-week-old animals, 
although Igf2 was strongly induced also in animals of other age (51). Together with the lack 
of effect of a neutralizing anti-IGF2 antibody these findings strongly suggest no direct 
signaling axis p62-IGF2-PI3-K/Akt. The different results between wortmannin vs. LY294002 
regarding the extent of apoptosis protection in p62-overexpressing cells is probably due the 
partial inhibition of proapoptotic p38 kinase by wortmannin (60).  
Our data clearly indicate that the antiapoptotic effect of p62 is rather facilitated via ERK 
phosphorylation. In fact, in a rodent model tumor growth and apoptosis resistance of 
intraperitoneally applied hepatoma cells was enhanced by overexpression of the ERK 
upstream kinase MEK1 (23), and overactivation of the MAPK pathway in liver tumor cells 
was reported to play a role in the initiation and development of HCC through resistance to 
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apoptosis (4). Silencing ERK1/2 expression using RNA interference also led to suppression of 
cell proliferation in other tumors, such as ovarian cancer (46). In addition to these findings in 
experimental systems, two clinical reports displayed aberrant ERK phosphorylation, ranging 
from 23 up to 69% of HCCs (23, 43). Interestingly, Schmitz et al. demonstrated ERK1/2 
phosphorylation to correlate with poor prognosis (43). Among the human HCC samples we 
also observed phosphorylation of ERK in cases with high p62 expression and poor outcome. 
There were also samples that were negative for phospho-ERK in tumor vessels, serving as 
staining control. We suggest that the detection of phospho-ERK might have failed, because 
the stabilization of phosphorylated proteins in formalin-fixed paraffin-embedded tissues is not 
always successful due to slow tissue penetration (35), and phosphorylation of ERK seems to 
be less stable as compared to other phospho-proteins (23). Therefore, an even higher 
frequency of HCC samples with ERK activation might be assumed.  
ERK phosphorylation is not only altered in malignant tissues, but also in patients with severe 
chronic hepatitis B virus (HBV) infection (19), suggesting a transition step towards HCC. In 
fact, in the context of both HBV and hepatitis C virus (HCV) infection, activation of the ERK 
pathway was demonstrated to enhance cell cycle progression, cell proliferation, and survival 
(15, 59). Concordantly, ERK phosphorylation was strongly correlated to HCV infection (43). 
We demonstrate for the first time that ERK phosphorylation in hepatoma cells, which leads to 
resistance against apoptosis, is due to expression of the IMP p62. In line with these findings, 
ERK also seems to be involved in modulating drug resistance of HCC cells (53). Clinical 
relevance is underlined by the suggestion of a combined doxorubicin and ERK targeted 
therapy with enhanced anti-cancer effects in HCC (10).  
Taken these findings together, p62 seems to play a dominant role in HCC progression and is 
accompanied by increased expression of the oncogene IGF2. Furthermore, p62-induced ERK 
activation seems to display a critical step in hepatocarcinogenesis. 
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A publication reporting that ELOVL6 was upregulated in a murine NASH model and in 
murine NASH-associated HCC (Muir et al., 2013) drew our attention, since ELOVL6 has 
been reported to promote NASH in mice and humans (Matsuzaka et al., 2012) and is also 
overexpressed in the p62-induced steatosis, which is accompanied by mild signs of 
inflammation (Laggai et al., 2014). However, the authors proposed ELOVL6 as a 
pharmacological target for the treatment of human HCC, without showing ELOVL6 
expression data or showing elevated fatty acid elongation in the human system (Muir et al., 
2013). Our own data obtained from the analysis of human HCC data from a Gene Expression 
Omnibus dataset and a murine HCC model suggested decreased expression of ELOVL6 in 
HCC.  
 
Lipid Metabolism Signatures in NASH-Associated HCC - Letter. 
Sonja M. Kessler, Stephan Laggai, Ahmad Barghash, Volkhard Helms, and Alexandra K. 
Kiemer. 
 
This research was originally published in Cancer Research. Kessler, S.M., Laggai, S., 
Barghash, A., Helms, V., and Kiemer A.K. Lipid Metabolism Signatures in NASH-
Associated HCC—Letter. Cancer Res. 2014; 74, 2903-2904. doi: 10.1158/0008-5472.CAN-
13-2852. Copyright © 2014, American Association for Cancer Research. 
 
The full text article can also be found at: 
http://cancerres.aacrjournals.org/content/74/10/2903.full.pdf+html 
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2.4.3 Letter 
An article published recently in Cancer Research elegantly performed lipidomic and gene 
expression analyses in a murine model of NASH-associated hepatocellular carcinoma (HCC) 
and compared the findings to serum samples from fibrosis and HCC patients (1). 
The study reports that the expression of the C18 fatty acid producing elongase 6 (ELOVL6) is 
elevated in a mouse non-alcoholic steatohepatitis model. The animals also exhibited elevated 
oleic acid (18:1n9) and vaccenic acid (18:1n7) abundance in livers and serum. Thereby, the 
study supports findings about increased hepatic ELOVL6 expression in other models of 
NASH, such as a fructose feeding model (2) and low-density lipoprotein receptor (LDLR) 
knockout animals fed a western type diet (3). In line with these findings, a causal role for 
ELOVL6 in the development of NASH was published recently in a comprehensive work 
employing overexpression and knockdown strategies (4).  
HCC represents a rare but important complication of non-alcoholic steatohepatitis (NASH) 
(5). The study by Muir et al. reports an increased expression of ELOVL6 not only in murine 
NASH but also in murine NASH-associated HCC. Because lipidomic analyses of sera of 15 
patients with HCC showed a higher prevalence of the C18 vaccenic acid (18:1n7) than serum 
of cirrhosis patients, the authors suggested elevated ELOVL6 expression in human HCC. 
Although they observed lower levels of the more abundant linoleic acid (18:2n6) and they do 
not show any data on ELOVL6 expression in patients with HCC, they propose ELOVL6 as a 
pharmacological target for patients predisposed to HCC. 
We investigated differential ELOVL6 gene expression between HCC (n=247) and non-tumor 
(n=239) samples of a Gene Expression Omnibus dataset (GSE14520, Fig. 1).  
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Figure 1: mRNA levels of ELOVL6 in 247 human HCC samples relative to the mean of 239 
non-tumor liver tissue (µnormal). Samples of dataset GSE14520 [log2 (expression) values from 
GEO after Robust Multi-array Average normalization] were mapped to hgu133a.db using 
bioconductor. Significance values: p=3.8E-11, Kolmogorov-Smirnov test; p= 6.7E-11 t-test; 
5.1E-11, Mann-Whitney U test. 
 
Interestingly, in contrast to Muir and colleagues, our results from this large data set revealed 
significantly decreased levels of ELOVL6 gene expression in the majority of human liver 
tumors compared to non-tumorous tissue. We also observed a decreased expression of Elovl6 
in the widely accepted murine diethylnitrosamine (DEN) HCC model (Fig. 2). 
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Figure 2: Wild-type mice were treated with the carcinogen diethylnitrosamine (DEN) at the 
age of 2 weeks. Livers were analyzed after 24 weeks to assess the tumor initiation state. 
Analyses in the tumor progression stadium were done after 36 weeks. Elovl6 mRNA 
expression as determined by real-time RT-PCR with n=8-18 per group. Data were normalized 
to 18s. Statistical differences compared to untreated animals of the same age (ctrl.) were 
calculated by Mann-Whitney U-test. 
 
Taken together, different recent reports from the literature suggest a pathophysiological role 
for ELOVL6 in steatohepatitis. Still, a role for ELOVL6 in HCC is as yet elusive and our data 
show ELOVL6 expression to be reduced in a common murine non-NASH-associated HCC 
model as well as in a large proportion of patients with HCC. In our opinion the data available 
on ELOVL6 in HCC do not justify proposing ELOVL6 as a therapeutic target in either 
prevention or treatment of HCC. 
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The following part contains new data, which will be submitted for publication after 
submission of my PhD thesis. 
 
3.1 Abstract 
p62 has been found to upregulate Igf2 and H19 mRNA expression in murine livers and our 
unpublished data suggest that p62 strongly amplifies tumor incidence. Igf2 and H19 genes are 
regulated by epigenetic mechanisms and are encoding for microRNAs. 
The aim of our study was to evaluate the impact of p62 on microRNA regulation and to link 
them to p62-mediated hepatocarcinogenesis. 
We performed microRNA array analysis of p62 transgenic livers and compared them to wild-
type controls. The microRNA array revealed an interesting effect of p62 on up to 25 
microRNAs located in the imprinted Dlk1 and Gtl2 (human homologue MEG3) domain, 
whereby the maternally expressed Gtl2 represents a non-coding microRNA precursor RNA.  
We could identify that p62 also induces miR-483 and -675, which are encoded by Igf2 and 
H19.  
The paternally expressed Dlk1 encodes for a protein, which has been suggested to be involved 
in hepatocarcinogenesis, we looked at Dlk1 and Gtl2 expression. In line with the finding that 
p62 induces the miRNAs located in the Dlk1-Gtl2 cluster, we were able to demonstrate that 
p62 also induces Dlk1 and Gtl2 mRNA and DLK1 protein in untreated animals. Besides, we 
found elevated levels of Dlk1 and the Rho GTPase Rac1 mRNAs in p62 transgenics 
challenged with the potent carcinogen DEN. RAC1 mRNA was regulated dependent on p62 as 
found in human HepG2 cells challenged by p62 knockdown or overexpression. An additional 
finding revealed that DLK1 induces RAC1.  
DLK1 and RAC1 might be responsible for ERK activation as found in p62 transgenic animals 
treated with or without DEN.  
Taken together, we could decipher parts of the pathway how p62 might exert its carcinogenic 
and antiapoptotic effects, which seems mainly mediated by affecting imprinting, regulation of 
microRNAs, and the activation of the ERK pathway via DLK1/RAC1. 
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3.2 Introduction 
Previous data showed that p62 acts as a regulator of gene expression with distinct effects on 
imprinted genes (Tybl et al., 2011) as well as metabolic and inflammatory regulators (Laggai 
et al., 2014; Simon et al., 2014a; Simon et al., 2014b). We hypothesized that p62 might exert 
its actions in liver pathophysiology also by affecting the expression of microRNAs (miRs). 
MicroRNAs are small non-protein-coding RNAs, which can negatively control their 
respective gene targets (Esquela-Kerscher and Slack, 2006). MicroRNAs are transcribed by 
RNA polymerase II, resulting in a large RNA precursor called primary microRNA, processed 
by the RNase III enzyme Drosha and the double-stranded-RNA-binding protein Pasha into the 
respective precursor microRNA (~70 nucleotides)(Lee et al., 2002). The precursor microRNA 
is cleaved by another RNase III enzyme called Dicer and the mature double-stranded 
microRNA (~22 nucleotides) is incorporated into the microRNA induced silencing complex 
(Meister, 2013), which finally can bind to and regulate its target RNAs. In addition to their 
action within their cell of origin, microRNAs can also be secreted into the circulating blood 
included in lipid or lipoprotein complexes, such as exosomes, and act by modulating the gene 
expression within their recipient cells (Hu et al., 2012). Circulating microRNAs were 
suggested as new biomarkers for liver diseases (Kosaka et al., 2010). 
MicroRNAs play a pivotal role also in the normal liver development. In this context, members 
of the miR-181 family are highly expressed in embryonic liver and involved in liver 
differentiation (Ji et al., 2009). Aberrant expression of microRNAs correlates with all stages 
of NAFLD (Wang et al., 2012) and in various human cancer types. MicroRNAs can act as 
tumor suppressors as well as oncogenes (Esquela-Kerscher and Slack, 2006). 
Literature regarding microRNA profiles and mechanisms in NAFLD is rather 
underrepresented compared to liver cancer. However, some microRNAs are regarded as 
potential biomarkers for NAFLD progression: 
miR-15b was elevated in two different NAFLD rat models (Zhang et al., 2013), and 
circulating levels of miR-122, -34a, -16 (Cermelli et al., 2011), and -15b were significantly 
higher in sera of NAFLD patients (Zhang et al., 2013). miR-29 was shown to be implicated in 
the regulation of human and murine liver fibrosis (Roderburg et al., 2011), and miR-106b and 
-181b were suggested as potential biomarkers for liver cirrhosis (Chen et al., 2013).  
MicroRNA profiling in liver cancer is currently the most studied topic regarding microRNAs 
in liver disease. There are several studies, which identified let-7, miR-122, -26, and -101 to be 
downregulated, and miR-221, -181, and -17-92 , -21 to be upregulated in serum and tissue of 
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HCC patients (Karakatsanis et al., 2013; Wang et al., 2014; Wang et al., 2012; Xu et al., 
2011; Xu et al., 2014). Reduced expression of miR-122 often correlates with poor prognosis 
(Coulouarn et al., 2009). Furthermore, miR-21 was highly upregulated in human HCC tissue 
and modulated the expression of the tumor suppressor phosphatase and tensin homolog, 
which was responsible for increased cell growth, migration, and invasion in human 
hepatocytes and liver cancer cell lines (Meng et al., 2007). 
The aim of our study was to decipher the influence of p62 on microRNA expression and to 
link them to p62-mediated pathophysiologic actions in the liver. 
 
3.3 Materials and Methods 
3.3.1 Animals 
All animal procedures were performed in accordance with the local animal welfare committee 
(permission 48/2009). p62 transgenic mice were established as previously described (Tybl et 
al., 2011). 
Mice were treated with diethylnitrosamine (DEN) at the age of two weeks by an 
intraperitonneal injection with 5 mg/kg body weight. Mice were sacrificed at the indicated 
time. All animal procedures were performed by Dr. Sonja M. Kessler (Pharmaceutical 
Biology, Saarland University, Saarbruecken, Germany). 
 
3.3.2 Cell culture experiments 
HepG2 cells were cultured in RPMI-1640 (Sigma Aldrich, Taufkirchen, Germany) with 
supplementation of 10% [v/v] FCS (Sigma Aldrich), 1% [v/v] glutamine (Sigma Aldrich), and 
1% [v/v] penicillin/streptomycin (Sigma Aldrich)
 
at 37°C and 5% CO2. 
Knockdown and overexpression experiments were performed as previously described (Laggai 
et al., 2014). 
HepG2 cells were treated with 1 µg/ml human recombinant DLK1 in complete RPMI-1640 
media for 48 h (1144-PR-025, R&D Systems, Minneapolis, USA). 
 
3.3.3 microRNA array 
The microRNA array was performed in cooperation with the group of Prof. Meese (Dr. Petra 
Leidinger, Humangenetik, Universitaetsklinikum Saarland, Homburg, Germany). RNA from 
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tissues were isolated using the miRNeasy mini kit (217004, Qiagen, Hilden, Germany), and 
the microRNA array was performed with a mouse miRNA microarray, Release 17.0, 8x60K 
(G4872A-035430, Agilent Technologies, Waldbronn, Germany) as recommended by the 
manufacturer. 
 
3.3.4 Real-time RT-PCR  
Real-time RT-PCR was performed as previously described (Laggai et al., 2014; Tybl et al., 
2011). Primer sequences and conditions can be found in the supplementary part (page 117-
119) 
 
3.3.5 Extracellular-signal regulated kinase (ERK) Western Blot 
ERK Western blot and analysis was performed by Dr. Sonja M. Kessler as previously 
described (Kessler et al., 2013).  
 
3.3.6 ELISA 
DLK1 ELISA was performed with a Mouse Protein delta homolog 1 (DLK1) ELISA kit 
(CSB-EL006945MO, Cusabio, Wuhan, China) as recommended by the manufacturer. 
 
3.3.7 Statistical analysis 
Statistical differences were estimated using the Mann-Whitney-U test or Fisher exact test 
(tumor incidence, 6 months, DEN mice). Calculations were performed using the software 
package Origin (Origin pro 8.6G, OriginLab Corporation, Northampton, USA). Pearson’s 
correlation was used to determine the relationship between Dlk1 and Rac1 in 8 months old 
transgenic animals treated with DEN. Values of p<0.05 were considered statistically 
significant. 
 
3.4 Results 
microRNA array analysis of most distinctly altered microRNAs in p62 transgenic mice 
revealed that microRNAs from the delta-like 1 homologue (Drosophila) (DLK1) / maternally 
expressed gene 3 (MEG3)(human), gene-trap locus 2 (Gtl2)(mouse) (MEG3/Gtl2) cluster 
were altered and showed a total regulation of 25 microRNAs (fold change > 1.4)(Fig. 3.1). 
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Fig. 3.1: p62-dependent changes in microRNA expression from the Dlk1-Gtl2 cluster. Total 
RNA from wild-type and p62 transgenic animals (5 weeks, n = 2, each) were analyzed by 
microRNA array. Results are presented as fold change compared to wild-type animals. 
 
Furthermore, data from the microRNA array revealed that p62 transgenic mice exhibited 
increased levels of miR-675-3p (1.7 fold, 5 weeks), which is encoded by H19 (Keniry et al., 
2012), and miR-483-3p (1.5 fold, 2.5 weeks), as an intronic transcript from the Igf2 gene (Liu 
et al., 2013). The paternally expressed IGF2 and the maternally expressed non-coding gene 
H19 are imprinted genes, which are co-expressed and respond in a reciprocal manner to loss 
of DNA methylation (Schmidt et al., 2000). 
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Also the Dlk1-Gtl2 cluster represents an imprinted genomic region. Gtl2 is a maternally 
expressed non-coding gene (Schmidt et al., 2000), which encodes for 54 microRNAs 
(Benetatos et al., 2013). With 25 of these microRNAs being regulated in p62 transgenic 
animals we hypothesized that p62 upregulates Gtl2 expression. We in fact found elevated 
levels of Gtl2 mRNA (Fig. 3.2A). Interestingly, DLK1/pre-adipocyte factor-1 (Pref-1) as a 
paternally expressed protein coding gene (Schmidt et al., 2000) was also elevated in our p62 
transgenics (Fig. 3.2B). Since only the secreted form of DLK1 is active (Wang et al., 2006), 
we validated the expression of the active form of DLK1 by ELISA in mouse serum (Fig. 
3.2C). 
  Unpublished data 
 
 104
 
Fig. 3.2: A) Real-time RT-PCR for Gtl2 mRNA expression from wild-type (wt) and p62 
transgenic mice (p62 tg) at the age of 2.5 (wt: n = 5, p62 tg n = 5) and 5 weeks (wt: n = 14; 
p62 tg: n = 15). B) Real-time RT-PCR for Dlk1 mRNA expression from wt and p62 tg at the 
age of 2.5 (wt: n = 5, p62 tg n = 5) and 5 weeks (wt: n = 14; p62 tg: n = 15). C) DLK1 ELISA 
of sera from 5 week old wt and p62 tg animals (wt, p62 tg: n=22, each). 
 
With DLK1 being an oncofetal marker (Falix et al., 2012) we hypothesized that elevated 
levels might support tumorigenic actions. We therefore challenged p62 transgenic and wild-
type mice with the carcinogen DEN in order to simulate states of tumor initiation and 
progression. We in fact observed a higher tumor incidence in p62 transgenic animals (Fig. 
3.3). 
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Fig. 3.3: Tumor incidence of wild-type (wt, n = 20) and p62 transgenic animals (p62 tg, n = 
20) 6 months after treatement with DEN (data provided by Dr. Sonja M. Kessler). 
 
DLK1 has been shown to activate extracellular-signal regulated kinase (ERK) by inducing 
ras-related C3 botulinum toxin substrate 1 (RAC1) in adipocytes (Wang et al., 2010). Since 
p62 induces ERK activation as an important tumor promoting protein kinase, we 
hypothesized that a similar signalling is induced by p62 during hepatocarcinogenesis. We in 
fact found increased levels of Dlk1, Gtl2, and Rac1 mRNA (Fig. 3.4A, B, C), DLK1 protein 
(Fig. 3.4E), and increased amounts of activated ERK in p62 transgenics (Fig. 3.4F). 
Interestingly, Dlk1 was significantly upregulated in tumor tissue compared to non-tumor 
tissue (Fig. 3.4A). Since Dlk1 showed only borderline significance in normal tissues of p62 
transgenic mice, we determined the interconnection between Dlk1 and Rac1 mRNA from 
these tissues by Pearson’s correlation and indeed found a strong correlation (Fig. 3.4D).  
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Fig. 3.4: A) Real-time RT-PCR for Dlk1 mRNA expression from wild-type (wt) and p62 
transgenic mice (p62 tg) at the age of 8 months treated with DEN, p62 tg: n = 18, each) and 
the corresponding normal and tumor tissue from p62 tg (wt, p62 tg: n = 15, each). B) Real-
time RT-PCR for Gtl2 mRNA expression from wt and p62 tg at the age of 8 months treated 
with DEN (wt, p62 tg: n = 18, each). C) Real-time RT-PCR for Rac1 mRNA expression from 
wt and p62 tg at the age of 8 months treated with DEN (wt, p62 tg: n = 18, each). D) Real-
time RT-PCR for Dlk1 and Rac1 of p62 tg at the age of 8 months treated with DEN (n = 18) 
normalized on 18s mRNA levels. E) DLK1 ELISA of sera from 6 months old wt and p62 tg 
animals treated with DEN (wt, p62 tg: n = 9, each). F) Phospho-ERK (pERK) Western blot 
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and quantification of livers from 6 months old wt and p62 tg animals normalized on total 
ERK (tERK)(wt, p62 tg: n = 9, each) (data provided by Sonja M. Kessler). 
 
We performed p62 knockdown and overexpression in human HepG2 cells and in line with the 
findings from p62 transgenic animals, we saw that RAC1 expression was dependent on p62 
expression: RAC1 was increased by overexpressing p62 (Fig. 3.5A) and decreased after p62 
knockdown (Fig. 3.5B). 
Since also HepG2 were susceptible to p62-mediated RAC1 induction, we used this HepG2 
model to validate that increased levels of Rac1 were dependent on increased DLK1 levels in 
our p62 transgenics. Therefore, we treated HepG2 cells with recombinant DLK1 and observed 
increased levels of RAC1 mRNA (Fig. 3.5C). 
 
Fig. 3.5: A) Real-time RT-PCR of HepG2 transfected with p62 overexpression vector (p62) 
or control vector (co-v) for RAC1 mRNA expression (n = 3, triplicate). B) Real-time RT-PCR 
of HepG2 transfected with p62 siRNA (si p62) or control siRNA (si co) for RAC1 mRNA 
expression (n = 3, quadruplicate). C) Real-time RT-PCR of HepG2 treated with soluble 
DLK1 at a concentration of 1 µg / ml or untreated control cells (co) for RAC1 mRNA 
expression (n = 3, duplicate). 
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3.5 Discussion 
Aberrant expression of microRNAs of the DLK1-MEG3 cluster, as also found in our p62 
transgenic animals, are common features in several cancer types, as recently reviewed in 
detail by Benetatos and colleagues (Benetatos et al., 2013). Interestingly, although the DLK1-
MEG3 cluster is encoding for at least 54 microRNAs (Benetatos et al., 2013) functional 
implications are rather uncharacterized. One publication suggests that the DLK1-MEG3 locus 
is frequently deregulated in human HCC (Anwar et al., 2012). Lim et al. recently found this 
cluster upregulated in a subtype of human HCC and in three transgenic mouse models and 
suggested miR-494 as a therapeutic target for the treatment of HCC (Lim et al., 2014). 
Interestingly, miR-494, among many other microRNAs of this cluster, was also upregulated 
in the presence of p62.  
A crucial role for the imprinted IGF2-H19 cluster in different cancer types is widely accepted 
(Kamikihara et al., 2005; Ohlsson et al., 1999; Sakatani et al., 2005). For example, loss of 
imprinting of the IGF2-H19 domain leads to the formation of the Beckwith-Wiedemann 
syndrome and Wilms’ tumor (Sakatani et al., 2005). The IGF2-H19 cluster is encoding for 
two microRNAs: The long non-coding RNA H19 encodes for miR-675 (Keniry et al., 2012), 
and miR-483 is encoded by intronic regions of the IGF2 gene (Liu et al., 2013). Data from 
our microRNA array indicated that miR-675 and miR-483 were upregulated and are in line 
with the finding that both Igf2 and H19 were strongly enhanced in p62 transgenic animals 
(Tybl et al., 2011). miR-675 suppresses growth and cell proliferation in different cell lines 
(Keniry et al., 2012) suggesting tumor-suppressive actions. On the other hand, miR-675 is 
upregulated in human adrenocortical carcinoma and metastases (Schmitz et al., 2011). miR-
483 enhances transcription of Igf2 and tumorigenesis (Liu et al., 2013), and was suggested as 
a potential biomarker for HCC (Shen et al., 2013). Colon organoid culture revealed miR-483 
as a dominant driver oncogene inducing dysplasia in vitro and tumorigenicity in vivo (Li et 
al., 2014). Taken together, p62 induces the expression of tumor-associated microRNAs. They 
might contribute to p62’s tumor-promoting actions found in DEN-treated animals. Further 
comprehensive analysis is required for a detailed mechanistic understanding. 
Since p62 induces the coordinated expression of the imprinted Igf2 and H19 genes in p62 
transgenic animals (Tybl et al., 2011) and their respective microRNAs, miR-483/miR-675, 
and p62 is also implicated in the regulation of the imprinted Dlk1-Gtl2 cluster in these mice 
leads us to speculate that p62 is a general regulator of imprinted genes. 
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We observed that DLK1 mRNA and protein was elevated in p62 transgenics. Interestingly, 
DLK1 protein has been shown to be expressed in hepatocellular, colon, pancreas, and breast 
carcinoma at a high frequency (Yanai et al., 2010). DLK1 is induced specifically in HCC 
tissue and not in adjacent tissue, and suppression of DLK1 in human cancer cell lines can 
inhibit cell growth, colony formation, and tumorigenicity (Huang et al., 2007). DLK1 is a 
transmembrane protein, which is cleaved by tumor necrosis factor converting enzyme, 
secreted in its soluble form, and can therefore act as an autocrine / paracrine factor (Hudak 
and Sul, 2013). Recently, DLK1 has also been reported as a serum marker of hepatoblastoma 
in young infants (Falix et al., 2012) and as a marker for stem cells (Falix et al., 2012; Oertel et 
al., 2008; Tanimizu et al., 2003). 
The finding that the antiapoptotic effect of p62 is dependent on the ERK signalling pathway 
and independent of IGF2 in p62 transgenic mice and human (Kessler et al., 2013) raised the 
question how p62 induces activation of the ERK pathway. 
The ERK signalling pathway plays a central role in cell proliferation and survival and 
increased ERK activity is found in many human cancer types (Montagut and Settleman, 2009; 
Thompson and Lyons, 2005). Also HCC is associated with overexpression and activation of 
ERK (Huynh et al., 2003) and activation of ERK correlates with poor prognosis (Schmitz et 
al., 2008). 
DLK1 has been shown to activate ERK (Niba et al., 2013; Wang et al., 2010), which was 
postulated to be mediated via RAC1 (Wang et al., 2010). 
RAC1 belongs to the family of small GTPases and controls cytoskeletal rearrengements and 
cell growth, is overexpressed in aggressive breast cancer (Schnelzer et al., 2000) and gastric 
cancer (Walch et al., 2008), and correlates with poor prognosis in HCC patients (Yang et al., 
2010). 
We found that DLK1 was strongly induced in our p62 transgenic animal model, and led to 
increased expression of RAC1 and activated ERK in DEN-challenged p62 transgenics as well 
as elevated RAC1 mRNA in a human cell line treated with DLK1 protein. HepG2 cells, in 
which p62 was modulated by knockdown or overexpression, revealed activated ERK levels 
(Kessler et al., 2013) corresponding to the levels of RAC1 found in this study. When p62 was 
absent, activated ERK and RAC1 levels decreased. Vice versa, when p62 was overexpressed 
activated ERK and RAC1 levels increased. Since DLK1 has been shown to induce the 
activation of ERK via RAC1 (Wang et al., 2010), we conclude that p62 induces DLK1 in our 
p62 transgenic animals, which leads to increased RAC1 levels and subsequent activation of 
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ERK (Fig. 3.6). We suppose that DLK1 might be the missing link for the mechanism how p62 
induces ERK activation. 
Taken together, our data show that p62 (I) promotes tumor development (Fig. 3.6), (II) 
deregulates microRNAs, which are involved in hepatocarcinogenesis (Fig. 3.6), (III) regulates 
imprinting networks linked to hepatocarcinogenesis, as found for the Igf2/H19 and Dlk1/Gtl2 
cluster (Fig. 3.6), and (IV) leads to the activation of the survival pathway ERK via 
DLK1/RAC1 (Fig. 3.6). 
 
 
Fig. 3.6: Mechanisms of p62-mediated ERK activation and cancer development. 
 
These findings support p62 as a potential biomarker and target for the treatment of HCC. 
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4 Extended summary 
The insulin-like growth factor 2 (IGF2) mRNA binding protein p62/IGF2B2-2/IMP2-2 
induces hepatic steatosis in mice, is overexpressed in patients with hepatocellular carcinoma 
(HCC), and is associated with the overexpression of the tumorigenic growth factor IGF2. 
With hepatic steatosis being a crucial step in HCC development, the mechanisms by which 
p62 promotes malignant transformations in liver disease progression are poorly characterized. 
Therefore, the aim of this study was to elucidate the implications of p62 on lipogenic and 
tumorigenic pathways. 
Since alterations in hepatic lipid and fatty acid composition are linked to liver pathogenesis 
we analyzed the liver lipids of p62 transgenic animals. Almost all lipid classes were elevated 
in the p62 transgenic livers, with triglycerides showing the strongest increase. The lipid 
profile indicated that p62 transgenic animals might develop signs of inflammation within their 
livers. Concordantly, we found elevated hepatic levels of the inflammatory marker F4/80 and 
leukocyte infiltrates (Fig. 4.1). 
The fatty acid composition revealed an increased ratio of C18 to C16 fatty acids. In line with 
this finding, the enzyme ELOVL fatty acid elongase 6 (ELOVL6), responsible for the 
elongation of C16 to C18 fatty acids and implicated in the development of steatohepatits, was 
upregulated by p62 and the subsequent induction of IGF2 (Fig. 4.1). Concordantly, we found 
that p62 and IGF2 mRNA strongly correlated with ELOVL6 mRNA also in human liver 
disease. IGF2 mediated its effect by inducing the maturation of sterol regulatory element 
binding transcription factor 1 (SREBF1) (Fig. 4.1), one of the pivotal transcriptional 
regulators of ELOVL6.  
p62-induced steatosis was not mediated by increased de novo lipogenesis, decreased 
peroxisomal lipid degradation, decreased lipid export, or increased lipid uptake in the liver. In 
fact, decreased levels of C16 fatty acids, elongated to C18 fatty acids by ELOVL6, were 
responsible for carnitine palmitoyltransferase 1A (CPT1A) inhibition and a subsequently 
decreased mitochondrial fatty acid degradation, which finally led to hepatic lipid 
accumulation and steatosis (Fig. 4.1). 
These results demonstrate an important role of p62 and p62-induced ELOVL6 levels in the 
development of steatosis and steatohepatitis.  
We found that p62 correlates with poor prognosis in patients with HCC, induces IGF2 in 
human hepatoma cell lines and exerts its antiapoptotic effect dependent on the extracellular-
signal regulated kinase (ERK) pathway (Fig. 4.1).  
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In HCC, however, the role of ELOVL6 is still elusive. We could demonstrate that ELOVL6 
was downregulated in a large proportion of HCC patients and in a murine HCC model. 
p62 amplifies HCC development, which might be partly attributed to delta-like 1 homolog 
(DLK1) mediated upregulation of ras-related C3 botulinum toxin substrate 1 (RAC1) and the 
subsequent activation of the antiapoptotic ERK pathway, as found in our p62 transgenic mice 
and cell culture experiments (Fig. 4.1). 
Taken together, our data underline the crucial role of p62 in liver diseases and provide further 
evidence that p62 might serve as prognostic marker and target for treatment options in liver 
diseases. 
 
 
Fig. 4.1: Summary: Pathophysiological effects of p62. 
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5.1 Supplemental materials and methods 
5.1.1 Preparation of nuclear extracts 
Nuclear extracts from HepG2 cells and murine liver tissue were prepared as described by 
Azzout-Marniche et al. (Azzout-Marniche et al., 2000). 500,000 cells in 2 ml media were 
grown over night in 6 well plates prior to the respective treatment. After the treatment, cells 
were washed twice with ice cold PBS and lysed in 100 µl buffer A and homogenized with a 
syringe and transferred to a clean vial. Liver tissue (approximately 100 mg) was homogenized 
in 200 µl buffer A with a pestle homogenizer (749540-0000, Kontes Glass Company, 
Vineland, USA) and a syringe. The cell or tissue lysates were centrifuged at 500 x g for 10 
min at 4 °C. The supernatant was transferred to a clean vial and stored at -80 °C until SDS-
PAGE as cytosolic fraction. The pellet was washed twice with buffer A. The washed pellet 
was resuspended in 20 µl (cells) or 50 µl (tissue) buffer B and incubated for 30 min on ice. 
Afterwards, the nuclear fraction was centrifuged at 12,000 x g for 30 min at 4 °C. The 
supernatant was stored at -80 °C and subjected to SDS-PAGE as nuclear fraction. Anti-lamin 
A/C antibody (#2032, Cell Signaling Technology, Danvers, USA) for nuclear fraction and 
anti-α–tubulin for cytosolic fraction were used as loading controls. 
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Buffer A: 
    1l    concentration 
Tris-HCl   1.6 g    10 mM 
NaCl    0.584 g   10 mM 
MgCl2x6H2O   0.61 g    3 mM 
--------------------------------------------- 
Freshly add to 5 ml Buffer A 
Nonidet P40   0.25 ml   0.5% 
Complete 7   0.83 ml   1x 
 
Buffer B: 
    1l    concentration 
HEPES   2.4 g    10 mM 
NaCl    58.44 g   0.42 M 
MgCl2x6H2O   0.3 g    1.5 mM 
Glycerol   25 ml    2.5% 
EDTA    0.37 g    1 mM 
EGTA    0.38 g    1 mM 
--------------------------------------------- 
Freshly add to 5 ml Buffer B 
DTT    50 µl    1 mM 
Complete 7   0.83 ml   1x 
  Supplemental part 
 
116 
5.1.2 Immunocytochemistry 
HepG2 cells were grown on coverslips. After 48 h they were washed with phosphate buffered 
saline (PBS, pH 7.4) and fixed with 4% paraformaldehyde in PBS for 10 min at RT. The 
samples were washed with ice cold PBS and incubated with 1% [m/v] BSA/10% [v/v] 
FCS/0.3 M glycin in PBS + 0.1% [v/v] Tween® 20. After washing with PBS, the primary 
antibodies against ELOVL6 (PRS4571, Sigma Aldrich, Taufkirchen, Germany), SREBF1 
(ab3259, Abcam, Cambridge, United Kingdom), and PDI (610946, BD Biosciences, Franklin 
Lakes, USA) were incubated at 1 µg/ml in PBS + 0.1% [v/v] Tween® 20 and 1% BSA [m/v] 
overnight at 4°C. The samples were washed with PBS and the secondary antibodies Alexa 
Fluor® 594 F(ab')2 fragment of goat anti-rabbit IgG (H+L) and Alexa Fluor® 498 F(ab')2 
fragment of goat anti-mouse IgG (H+L) (A-11037, A-11017, Life technologies, Darmstadt, 
Germany) was added in a dilution of 1:1,000 in PBS + 0.1% [v/v] Tween® 20 and 1% BSA 
[m/v] for 1 h at RT under exclusion of light. After washing with PBS, the samples were 
treated with 0.2 µg/ml diaminophenylindol HCl (DAPI) (D9542, Sigma Aldrich, Taufkirchen, 
Germany) for 1 min. The cells were washed with PBS, mounted in FluoroSafe™ mounting 
medium (#345789, Merck, Darmstadt, Germany), and visualised with an inverse fluorescence 
microscope (Axio Observer, Zeiss, Feldbach, Swiss). 
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5.1.3 Primer and conditions 
 
gene forward primer 
sequence 5´-3´ 
reverse primer 
sequence 5´-3´ 
amplicon 
size 
[bp] 
gene bank 
accession 
number 
primer 
amount 
[µl/reaction 
[10 µM]] 
/  
annealing 
temp [°C] 
huACTB TGCGTGACATTAAGGAGAAG 
GTCAGGCAGCTCG
TAGCTCT 107 NM_001101 
0.4 
60 
huACACA TCCGACCAGTAATCACTTTGC 
GGGAACGTTATCC
CCAAACC 139 NM_198834.1 
0.5 
60 
huELOVL6 CACTGTGAGCTGGAAAAGGGAG 
GTGTGAAGTCAAA
CAGGGAGGG 104 NM_024090.2 
0.4 
60 
huFASN ACTTCCCCAACGGTTCAGGTTC 
GCGTCTTCCACAC
TATGCTCAG 150 NM_004104.4 
0.4 
62 
huGCK CCTTACGCTCCAAGGCTACA 
TCTCTCCGAGGGG
CTAAGAG 93 NM_033508.1 
0.4 
60 
huIGF2 GGACTTGAGTCCCTGAACCA 
TGAAAATTCCCGT
GAGAAGG 100 NM_000612 
0.5 
56 
huMLXIPL CCCAAGTGGAAGAATTTCAAAG 
CTCTTCCTCCGCTT
CACATACT 110 NM_032952.2 
0.4 
59 
huNR1H3 TCATCAACCCCATCTTCGAG 
GCAATGAGCAAGG
CAAACTC 79 NM_005693 
0.2 
60 
hup62 GTTCCCGCATCATCACTCTTAT 
GAATCTCGCCAGC
TGTTTGA 117 AF057352 
0.4 
62 
huPKLR CCCACACTGAAAGCATGTCG 
CTCCTGGAGCCCC
AATCAG 114 NM_000298.5 
0.4 
60 
huPPARA TGCGTAGAAGAGCCCAGAAA 
GTTGACTGGACGG
AGCTGAG 137 NM_001001928.2 
0.2 
60 
huRAC1 AAGAGAAAATGCCTGCTGTTGTAA 
GCGTACAAAGGTT
CCAAGGG 72 NM_006908.4 
0.4 
60 
huSCD GCCAATTTCCTCTCCACTGCTG 
AAGTTCGCTCTTA
GAAGCTGCC 80 NM_005063.4 
0.4 
60 
huSREBF1 CCATGGATTGCACTTTCGAA 
GGCCAGGGAAGTC
ACTGTCTT 66 NM_001005291.2 
0.4 
60 
Suppl. table 1: Real-time RT-PCR primer and conditions for human genes and 5 x HOT 
FIREPol® EvaGreen® 
  Supplemental part 
 
118 
 
gene forward primer 
sequence 5´-3´ 
reverse primer 
sequence 5´-3´ 
amplicon 
size 
[bp] 
gene bank 
accession 
number 
primer 
amount 
[µl/reaction 
[10 µM]] 
/ 
annealing 
temp. [°C] 
mu18s GTAACCCGTTGAACCCCATT 
CCATCCAATCGGT
AGTAGCG 151 NR_003278.1 
0.4 
58 
mu91H CCGTGTGCTTGAGGCCTCGCCT 
CAACCTCCCCCCA
TGAGTCG 194 
NR_001592.1 
NC_000073.6 
0.4 
61 
muAire CGGAGCTACCTGCAGAGAC 
GTGACAGCAGCAT
CAGAGC 106 NM_009646 
0.3 
55 
muDlk1 ACTTGCGTGGACCTGGAGAA 
CTGTTGGTTGCGG
CTACGAT 221 NM_010052.5 
0.3 
58 
muF4/80 / 
EMR1 
CTTTGGCTATGGG
CTTCCAGTC 
GCAAGGAGGACA
GAGTTTATCGTG 165 NM_010130 
0.3 
60 
muElovl6 ACAATGGACCTGTCAGCAAA 
GTACCAGTGCAGG
AAGATCAGT 119 NM_130450.2 
0.2 
60 
muGtl2 AAGCACCATGAGCCACTAGG 
TTGCACATTTCCT
GTGGGAC 288 NR_104450.1 
0.4 
62 
muH19spec GGAGACTAGGCCAGGTCTC 
GCCCATGGTGTTC
AAGAAGGC 159 
NR_001592.1 
reverse primer 
0.5 
60 
muIl1β GAGAGCCTGTGTTTTCCTCC 
GAGTGCTGCCTAA
TGTCCC 115 NM_008361.3 
0.5 
60 
muMlxipl CTGGGGACCTAAACAGGAGC 
GAAGCCACCCTAT
AGCTCCC 166 NM_021455.4 
0.5 
60 
mup62 TTGGATGGGCTGTTGGCTGA 
GTGACGTTGACAA
CGGCAGTT 86 NM_183029.2 
0.4 
60 
muPpara CCTTCCCTGTGAACTGACG 
CCACAGAGCGCTA
AGCTGT 77 NM_001113418.1 
0.5 
60 
muRac1 GCGAAAGAGATCGGTGCTGT 
GACAGAGAACCGC
TCGGATAG 100 NM_009007.2 
0.4 
62 
muPten GTGAGGATGGTAGGGGAAT 
CACCACGCTTCAA
AGAGAAA 88 NM_008960.2 
0.4 
60 
muWnt10b ATCGCCGTTCACGAGTGTC 
GGAAACCGCGCTT
GAGGAT 111 NM_011718.2 
0.4 
61 
Suppl. table 2: Real-time RT-PCR primer and conditions for murine genes and 5 x HOT 
FIREPol® EvaGreen® qPCR Mix. 
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gene forward primer 
sequence 5´-3´ 
reverse primer 
sequence 5´-3´ Probe, 5’-3’ 
amplicon 
size 
[bp] 
gene bank 
accession 
number 
dNTPs 
/ 
Probe 
[pmol] 
MgCl2 
/ 
Temp 
[°C] 
cyclophillin GGCCGATGACGAGCCC 
TGTCTTTGG
AACTTTGTC
TGC 
TGGGCCGC
GTCTCCTT
CGA 
64 NM_008907.1 
125 µM 
1.5 
3 mM 
60 
H19 CAGAGGTGGATGTGCCTGCC 
CGGACCATG
TCATGTCTTT
CTGTC 
TCACTGAA
GGCGAGG
ATGACAG
GT GTGG 
80 NR_001592.1 
125 µM 
2.5 
3 mM 
58 
Igf2 
GGAAGTCGAT
GTTGGTGCTTC
TC 
CGAACAGAC
AAACTGAAG
CGTGT 
CCTTCGCC
TTGTGCTG
CATCGCTG
CT 
121 NM_010514.3 
125 µM 
1.5 
4 mM 
60 
Suppl. table 3: Real-time RT-PCR primer and conditions for murine genes and taq man 
probes (6-FAM-BHQ1). 
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5.1.4 Antibodies and conditions 
 
primary antibodies  
(anti-human/mouse) dilution buffer temp. Time 
manufacturer / 
order number 
anti-p62, rabbit IgG 1:1,000 in PBST + 5% BSA RT 2 h 
selfmade; Zhang et al. 
1999 
anti-alpha-tubulin, mouse IgG 1:1,000 in PBST + 5% dry milk RT 2 h 
Sigma Aldrich 
T9026 
anti-SREBF1, mouse IgG 1:200 in RBB RT 2 h 
Abcam 
ab3259 
[2A4] 
anti-PPARA; rabbit IgG 1:1,000 in PBST + 5% dry milk 4°C overnight 
Abcam 
ab8934 
anti-ELOVL6, rabbit IgG 1:1,000 in PBST + 5% BSA 4°C overnight 
Sigma Aldrich 
PRS4571 
anti-FASN, rabbit IgG 1:1,000 in RBB RT 2 h 
Cell Signaling 
Technology 
#3180 
[C20G5] 
anti-lamin A/C, rabbit IgG 1:1,000 in RBB 4°C overnight 
Cell Signaling 
Technology 
#2032 
Suppl. table 4: Antibodies and conditions for Western blot analysis. 
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5.2 Supplemental figures 
The following figures show results obtained within the PhD thesis from gene expression 
analysis by Real-time RT-PCR done on tissue from DEN-treated animals. They either 
revealed non-statistically significant effects for p62 or are related to other projects. This is 
why they will not be discussed in detail. 
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Suppl. Fig. 1: mRNA expression in livers from wild-type (co wt) and p62 transgenic mice 
(co p62 tg) (co wt, co p62 tg, n = 5, each) and mice treated with DEN for 4 h (DEN 4 h wt, 
p62 tg: n = 6, each) or 48 h (DEN 48 h wt, n = 14, p62 tg, n = 10) (permission 13/2009) for 
A) transgenic human p62 (hu p62), B) endogenous murine p62 (mu p62), C) Gtl2, D) Dlk1, 
and E) Elovl6. 
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Suppl. Fig. 2: mRNA expression in livers from wild-type (co wt) and p62 transgenic mice 
(co p62 tg) (co wt, co p62 tg: n = 5, each) and mice treated with DEN for 4 h (DEN 4 h wt, 
p62 tg: n = 6, each) or 48 h (DEN 48 h wt, n = 14, p62 tg, n = 10) (permission 13/2009) for  
A)Wnt10b, and B) Il1β. 
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Suppl. Fig. 3: mRNA expression in livers from wild-type (co wt, n = 8) and p62 transgenic 
mice (co p62 tg, n = 5) and mice treated with DEN (DEN wt, p62 tg: n = 20, each) 
(permission 48/2009) for 
A) transgenic human p62 (hu p62), B) endogenous murine p62 (mu p62), C) Igf2, D) H19 
using primer, which recognize both H19 and antisense 91H, E) H19 using primer specific for 
H19, and F) 91H. 
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Suppl. Fig. 4: mRNA expression in livers from wild-type (co wt, n = 8) and p62 transgenic 
mice (co p62 tg, n = 5) and mice treated with DEN (DEN wt, p62 tg: n = 20, each) 
(permission 48/2009) for 
A) Gtl2, B) Dlk1, C) Elovl6, and D) Pten. 
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Suppl. Fig. 5: mRNA expression in livers from wild-type (co wt, n = 8) and p62 transgenic 
mice (co p62 tg, n = 5) and mice treated with DEN (DEN wt, p62 tg: n = 20, each) 
(permission 48/2009) for 
A) Rac1, B) Tgf-β, and C) Wnt10b. 
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Suppl. Fig. 6: mRNA expression in livers from wild-type (co wt, n = 10) and p62 transgenic 
mice (co p62 tg, n = 13) and mice treated with DEN (DEN wt, p62 tg: n = 18, each) and the 
respective normal and tumor tissue from DEN-treated wt (n = 6, each, male) and p62 tg (n = 
15, each, n = 8 male, n = 7 female) (permission 48/2009) for 
A) transgenic human p62 (hu p62), B) endogenous murine p62 (mu p62), C) Igf2, D) H19 
using primer, which recognize both H19 and antisense 91H, E) H19 using primer specific for 
H19, and F) 91H. 
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Suppl. Fig. 7: mRNA expression in livers from wild-type (co wt, n = 10) and p62 transgenic 
mice (co p62 tg, n = 13) and mice treated with DEN (DEN wt, p62 tg: n = 18, each) and the 
respective normal and tumor tissue from DEN-treated wt (n = 6, each, male) and p62 tg (n = 
15, each, n = 8 male, n = 7 female) (permission 48/2009) for 
A) Aire, B) Zac1, C) Gtl2, D) Dlk1, E) Elovl6, and F) Pten. 
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Suppl. Fig. 8: mRNA expression in livers from wild-type (co wt, n = 10) and p62 transgenic 
mice (co p62 tg, n = 13) and mice treated with DEN (DEN wt, p62 tg: n = 18, each) and the 
respective normal and tumor tissue from DEN-treated wt (n = 6, each, male) and p62 tg (n = 
15, each, n = 8 male, n = 7 female) (permission 48/2009) for 
A) Rac1, B) Tgf-β, and C) Wnt10b. 
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ER ELOVL6 Overlay
10 µm
 
Suppl. Fig. 9: ELOVL6 is located in the endoplasmatic reticulum (ER), 
Immunocytochemistry of HepG2 cells. Left (green) ER (PDI), middle (red) ELOVL6, right 
merge, (blue) nucleus (DAPI). 
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